

## Review

## Neuroprotection by adenosine in the brain: From A<sub>1</sub> receptor activation to A<sub>2A</sub> receptor blockade

Rodrigo A. Cunha

*Center for Neuroscience of Coimbra, Institute of Biochemistry, Faculty of Medicine, University of Coimbra, Coimbra, Portugal*

Received 3 September 2004; accepted in revised form 10 November 2004

**Key words:** A<sub>1</sub> receptors, A<sub>2A</sub> receptors, adenosine, adenosine kinase, brain, neuroprotection

### Abstract

Adenosine is a neuromodulator that operates via the most abundant inhibitory adenosine A<sub>1</sub> receptors (A<sub>1</sub>Rs) and the less abundant, but widespread, facilitatory A<sub>2A</sub>Rs. It is commonly assumed that A<sub>1</sub>Rs play a key role in neuroprotection since they decrease glutamate release and hyperpolarize neurons. In fact, A<sub>1</sub>R activation at the onset of neuronal injury attenuates brain damage, whereas its blockade exacerbates damage in adult animals. However, there is a down-regulation of central A<sub>1</sub>Rs in chronic noxious situations. In contrast, A<sub>2A</sub>Rs are up-regulated in noxious brain conditions and their blockade confers robust brain neuroprotection in adult animals. The brain neuroprotective effect of A<sub>2A</sub>R antagonists is maintained in chronic noxious brain conditions without observable peripheral effects, thus justifying the interest of A<sub>2A</sub>R antagonists as novel protective agents in neurodegenerative diseases such as Parkinson's and Alzheimer's disease, ischemic brain damage and epilepsy. The greater interest of A<sub>2A</sub>R blockade compared to A<sub>1</sub>R activation does not mean that A<sub>1</sub>R activation is irrelevant for a neuroprotective strategy. In fact, it is proposed that coupling A<sub>2A</sub>R antagonists with strategies aimed at bursting the levels of extracellular adenosine (by inhibiting adenosine kinase) to activate A<sub>1</sub>Rs might constitute the more robust brain neuroprotective strategy based on the adenosine neuromodulatory system. This strategy should be useful in adult animals and especially in the elderly (where brain pathologies are prevalent) but is not valid for fetus or newborns where the impact of adenosine receptors on brain damage is different.

**Abbreviations:** A $\beta$  –  $\beta$ -amyloid peptide; A<sub>1</sub>Rs – A<sub>1</sub> receptors; A<sub>2A</sub>Rs – A<sub>2A</sub> receptors; CGS 21680 – 2-[4-(2-*P*-carboxyethyl)phenylamino]-5'-N-ethylcarboxamido-adenosine; CGS 15943 – 9-chloro-2-(2-furyl)(1,2,4)triazolo(1,5-c)quinazolin-5-amine; CPA – N<sup>6</sup>-cyclopentyladenosine; CSC – 8-(3-chlorostyryl)caffeine; DMPX – 3,7-dimethyl-1-propargylxanthine; DPCPX – 1,3-dipropyl-8-cyclopentyladenosine; KW6002 – (E)-1,3-diethyl-8-(3,4-dimethoxystyryl)-7-methyl-3,7-dihydro-1H-purine-2,6-dione; MPTP – 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SCH 58261 – 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-(4,3-e)-(1,2,4-triazolo(1,5-c)(pyrimidine); ZM 241385 – 4-(2-(7-amino-2(2-furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino)ethyl)phenol

### Introduction

Adenosine is a purine nucleoside that exists in all cells, where it is a metabolite involved in key pathways of primary metabolism such as nucleotide and nucleoside metabolism, sulphur-containing amino acid metabolism, *trans*-methylation reactions and handling of ammonia. Its intra-cellular concentration in basal conditions is typically around 10–50 nM in the cell types where it was so far quantified (reviewed in Cunha [1]). This intracellular concentration of adenosine is tightly linked to the energy charge of the

cells, in the sense that small decreases in the energy charge (sometimes considered equivalent to the concentration of ATP) cause a disproportionate larger increase in the intracellular levels of adenosine (reviewed in Cunha [1]). The impact of changes in the intracellular levels of adenosine on the primary metabolism has not yet been explored. However, because all cell types so far investigated possess bi-directional non-concentrative nucleoside transporters, the intracellular levels of adenosine equilibrate with the extracellular levels of adenosine. Thus, if the levels of intracellular adenosine rise in a particular cell, a gradient of increased levels of extracellular adenosine will build-up in the surroundings of this cell. This extracellular adenosine is then able to act on metabotropic adenosine receptors located in the cell membrane of neighbouring cells (as well as of the cell that released adenosine). The

Correspondence to: Dr Rodrigo A. Cunha, Center for Neuroscience of Coimbra, Institute of Biochemistry, Faculty of Medicine, University of Coimbra, 3004-504 Coimbra, Portugal. Tel: +351-238-820190; Fax: +351-239-822776; E-mail: [racunha@clix.pt](mailto:racunha@clix.pt)

activation of the different types of adenosine receptors (reviewed in the section “Adenosine receptors”) can then modify cell metabolism according to the set-up of adenosine receptors and to the primary metabolism of each particular cell type. In general, most mammalian cell types are equipped with adenosine  $A_1$  receptors ( $A_1$ Rs), whose activation causes a decrease in the rate of metabolism, allowing the cell to cope better with noxious stimuli. Thus, adenosine fulfils an homeostatic role in most cell types (see [2]), whereas a noxious stimuli reaching a particular cell causes a slight drop in energy charge that is converted into a large change in the intracellular levels of adenosine that diffuses out of the cell and signals to neighbouring cells via  $A_1$ Rs the presence of a noxious stimuli, preparing neighbouring cells to handle better this noxious stimuli (by generally decreasing their rate of metabolism).

This review will concentrate on the role of adenosine in the realm of neuroprotection, focusing on the brain. It should be kept in mind that the homeostatic role of adenosine described above occurs in the brain as it occurs in most mammalian tissues. But adenosine fulfils other particular roles in the brain, apart from its general homeostatic role. In fact, the brain is the tissue by far with the greatest density of the most abundant adenosine  $A_1$ Rs, which play key roles in controlling neuronal excitability and in particular neurotransmitter release, as will be discussed in the section “Modulatory roles of adenosine.” And several lines of evidence (reviewed in Cunha [1]) indicate that this particular neuromodulatory role of adenosine is independent of changes in the energy charge of brain cells, i.e. the neuromodulatory role of adenosine is independent of the homeostatic role of adenosine.

It is important to emphasise that adenosine behaves as a typical neuromodulator in the brain. In fact, adenosine signalling is designed to control the flow of information between neurons in the brain, rather than to directly transfer information between neurons, as occurs for neurotransmitters. And in contrast to typical neurotransmitters, there is no evidence available (well on the contrary) for an accumulation of adenosine in synaptic vesicles or for a release of adenosine in a quantal manner. However, as shall be discussed in the section “Generation of extracellular adenosine,” the build-up of extracellular adenosine in synapses is closely connected with the release of neurotransmitters and is tightly linked to the frequency and intensity of neuronal firing.

### Adenosine receptors

There are four types of membrane-bound adenosine receptors, named  $A_1$ ,  $A_{2A}$ ,  $A_{2B}$  and  $A_3$  receptors. These receptors have been cloned in different species and are all seven membrane-spanning metabotropic receptors that have, so far (but see [3]), been shown to couple via G proteins (reviewed in [4]). Traditionally, adenosine receptors were divided into two broad groups:  $A_1$ Rs and  $A_3$ Rs that would negatively couple to adenylate cyclase and  $A_{2A}$ Rs and  $A_{2B}$ Rs that would positively couple to adenylate cyclase.

However, this classification is now difficult to accept because all adenosine receptors have been shown to couple to different G proteins and to different transducing systems in different cell types. Thus, it appears that all adenosine receptors are fundamentally pleiotropic receptors, i.e. receptors with the potential to couple to different G proteins and to different transducing systems according to their degree of activation and with their particular cellular and sub-cellular localization. It is important to emphasise that the long-time assumed relation between brain adenosine receptors and cAMP is mostly of historical interest. For instance, the more widespread effect of adenosine in the brain (inhibition of neurotransmitter release by the most abundant  $A_1$ Rs) is now well established to be independent of the control of cAMP levels. This obviously does not exclude that some effects of adenosine receptors in the brain are actually mediated by cAMP, in particular important effects of adenosine like the  $A_1$ R-mediated neuronal hyperpolarization or  $A_{2A}$ R-mediated signal integration in striato-pallidal neurons.

Out of the four adenosine receptors, the  $A_1$ R is the most abundant and widespread in the brain (see, e.g., [5]).  $A_{2A}$ Rs are concentrated in the basal ganglia (reviewed in [6]), but they are also present throughout the brain albeit with a considerably lower density (discussed in “Modulatory roles of adenosine”). For these two main adenosine receptor subtypes, there are now good pharmacological tools as well as receptor knockout mice strains to probe their role in the brain. Thus, the role of  $A_1$ Rs is explored taking advantage of the selectivity of agonists such as CPA and antagonists such as DPCPX, whereas the role of  $A_{2A}$ Rs has been investigated based on the use of its selective antagonist SCH 58261 (and also other less selective antagonists such as ZM 241385, CSC or KW6002). Activation of  $A_{2A}$ Rs can be achieved with its agonist CGS 21680 but care is required to exclude the involvement of  $A_1$ Rs to which CGS 21680 also binds [7, 8] and activates (e.g., [9]).

Because of their low abundance in the brain, the role of  $A_{2B}$ Rs and  $A_3$ Rs has received considerably less attention. Thus, the role of adenosine in the brain is currently considered to be mediated by a balanced activation of  $A_1$  and  $A_{2A}$  receptors, as shall be detailed in this review. It is hoped that greater experimental efforts as well as novel tools will allow a novel perspective on the eventual relevance of the less abundant  $A_{2B}$ Rs and  $A_3$ Rs.

It is also relevant to mention that the traditional idea of  $A_1$ Rs and  $A_{2A}$ Rs as individual signalling systems may also need to be revised. As illustrated in Figure 1, molecular studies have opened the possibility of conceiving novel entities involving adenosine receptors, which may either be homodimers of either  $A_1$ Rs [10] or  $A_{2A}$ Rs [11] or heterodimers. The heterodimers so far identified can involve  $A_1$ Rs with either P2Y<sub>1</sub>Rs (a metabotropic receptor for ATP) [12] or metabotropic glutamate type 1 receptors [13] as well as  $A_{2A}$ Rs with either dopamine D<sub>2</sub>Rs [14] or metabotropic glutamate type 5 receptors [15, 16]. Although the functional relevance of most of these dimers involving adenosine receptors remains to be determined, this notion of receptor dimerization clearly widens the possible impact of adenosine on brain function and demands a re-

evaluation of our current pharmacological classification of adenosine receptor-mediated effects.

### Subcellular localization of adenosine receptors

Although  $A_1$ Rs, and also  $A_{2A}$ Rs, are widespread in the brain, they are not homogeneously located in neurons and other cell types in the brain. Thus, the investigation of their cellular and subcellular localization may provide a first insight on the possible modulatory role(s) that may be fulfilled by adenosine in the brain.

Although  $A_1$ Rs are most abundant in limbic and neocortical regions, they are also abundant in the basal ganglia and cerebellum and are also present in most nuclei in the diencephalon and brain stem (see [5] for a detailed mapping of the relative densities of brain  $A_1$ Rs).  $A_1$ Rs are considerably more abundant in neurons, but they are also present in astrocytes [17], microglia [18] and oligodendrocytes [19], albeit with a much lower density. The localization of  $A_1$ Rs in neurons is also highly asymmetric. Immunohistochemical studies of  $A_1$ R localization in brain preparations mostly concluded that  $A_1$ Rs displayed a predominant axonal localization (see [20]). This probably reflects the general low accessibility of antibodies to extracellular epitopes located in the synaptic cleft, which is densely packed with adhesion molecules [21]. In fact, when using radioligands or antibodies following cellular fractionation, it is concluded that  $A_1$ Rs are most abundant in synapses [22], in particular in the presynaptic active zone and post-synaptic density [23]. Functional data also indicate that the efficiency of  $A_1$ R activation (and probably  $A_1$ R density) is also different amongst different types of nerve terminals. In fact,  $A_1$ Rs efficiently control the release of glutamate, acetylcholine and serotonin, but several studies have documented the inability of  $A_1$ Rs to modulate the release of GABA and of noradrenaline in the brain (reviewed in [1]). This leads to the idea (detailed in “Modulatory roles of adenosine”) that  $A_1$ Rs mainly fulfil a synaptic neuromodulatory role in particular in excitatory nerve terminals in the brain.

In contrast to the widespread distribution of  $A_1$ Rs in the brain,  $A_{2A}$ Rs are highly concentrated in the basal ganglia (reviewed in [24]), where their density is about 20 times greater than elsewhere in the brain [7]. In the basal ganglia,  $A_{2A}$ Rs are predominantly located in dendritic spines [25] and post-synaptic densities [26] of asymmetric contacts between cortico-thalamic glutamatergic projections and medium spiny GABAergic neurons, as well as symmetric contacts between medium spiny neurons (see [25, 27]). In fact, striatal  $A_{2A}$ Rs are almost segregated to a particular sub-type of medium spiny neurons, the enkephalin-containing medium spiny neurons that constitute the indirect pathway (see [24]), where they are located post-synaptically controlling the integration of signal responses in these neurons (see reviews in [6, 24, 28]). This high density of striatal  $A_{2A}$ Rs has led to the erroneous idea that  $A_{2A}$ Rs were *exclusively* located in the basal ganglia. However, both *in situ* hybridization [29], binding [7], immunological

[30, 31] and functional studies [31, 32] have concurred to the conclusion that  $A_{2A}$ Rs are located in limbic and neocortical regions in the brain. And in these regions,  $A_{2A}$ Rs have a localization fundamentally different from that found in the striatum. In fact, cortical  $A_{2A}$ Rs are predominantly located in synapses, in particular in the presynaptic active zone [33]. And as discussed in “Modulatory roles of adenosine,” this localization of  $A_{2A}$ Rs is in agreement with the predominant role of extra-striatal  $A_{2A}$ Rs in the control of the release of neurotransmitters (reviewed in [1]). Again, in contrast to  $A_1$ Rs,  $A_{2A}$ Rs seem to have a broader localization (although at a considerably lower density) in different types of nerve terminals. In fact, extra-striatal  $A_{2A}$ Rs can not only control the release of glutamate (e.g., [32]), acetylcholine (e.g., [30, 34–36]), but can also control the release of GABA [37] and of noradrenaline [38], which are mostly insensitive to  $A_1$ R activation. Apart from their presynaptic localization,  $A_{2A}$ Rs are also located in astrocytes [39, 40] and microglia cells [41, 42] as well as in brain blood vessels [43, 44], most likely in endothelial cells.

In conclusion, throughout the brain, there is predominant synaptic localization of both  $A_1$  and  $A_{2A}$  receptors. Both  $A_1$ Rs and  $A_{2A}$ Rs are mostly located presynaptically and  $A_1$ Rs also have a dense post-synaptic localization. The striatum is clearly the exception, where  $A_{2A}$ Rs are most densely located post-synaptically. Apart from this predominant neuronal localization, both  $A_1$ Rs and  $A_{2A}$ Rs are also located in astrocytes and microglia and  $A_1$ Rs are located in oligodendrocytes and  $A_{2A}$ Rs in blood vessels.

The rest of the review will mostly concentrate on the role of  $A_1$  and  $A_{2A}$  receptors in mediating the effects of adenosine in the brain. In fact, because of the lack of selective pharmacological tools and of their low density in the brain, the possible roles of  $A_3$ Rs and  $A_{2B}$ Rs in the brain are still largely unexplored. However, it should always be kept in mind that both  $A_3$ Rs and  $A_{2B}$ Rs are also present in the brain. Thus, the presence of  $A_3$ Rs has been defined in neurons, both with binding [45], immunological [46] and functional studies [47, 48] but their function seems more evident in astrocytes (e.g., [49]) and eventually in microglia [50]. With respect to  $A_{2B}$ Rs, they are not present in microglia [50] but are mainly located in astrocytes (e.g., [51]). Some functional studies also indicate their possible presence in neurons (e.g., [52]) although molecular evidences for their neuronal location are still lacking.

### Modulatory roles of adenosine

As inferred from the presentation made on the localization of adenosine receptors, it is expectable that the main effect of adenosine on brain function might be a presynaptic control of the release of neurotransmitters. Also, based on the considerably greater density of  $A_1$ Rs compared to other adenosine receptor subtypes in the brain (excepting the basal ganglia), it is also expectable that the predominant effect of adenosine in the brain might be an inhibition of neurotransmitter release. And, in accordance with these




Figure 1. Ability of adenosine  $A_{2A}$  receptors ( $A_{2A}$ Rs) to fine-tune the efficiency of functioning of different other modulatory systems operated by either metabotropic, ionotropic or catalytic receptors. Activation of  $A_{2A}$ Rs can either inhibit (–) or facilitate (+) the receptors using either protein kinase A (PKA) or C (PKC) as transducing pathways. Note that this modulation of different systems is a compilation and does not imply that  $A_{2A}$ Rs affect all these transducing pathways in the same cell or that each target is always under the control of  $A_{2A}$ Rs.

predictions, electrophysiological studies of the role of adenosine in brain slices have concluded that adenosine mainly inhibits neuronal excitability and synaptic transmission (reviewed in [53–55]). This inhibitory effect of adenosine is mediated by  $A_1$ Rs and, accordingly, adenosine is nearly devoid of effects of synaptic transmission and neuronal excitability in brain slices in the  $A_1$ R knockout mice [56].

The adenosine  $A_1$ R-mediated inhibition of neuronal excitability and synaptic transmission is a dual role exerted in different neuronal compartments, both concurring to refrain neuronal activity. In fact,  $A_1$ R activation inhibits excitatory synaptic transmission, mostly through a presynaptic inhibition of glutamate release [57, 58]. This tonic presynaptic control by  $A_1$ Rs has recently been shown to be a key factor in defining the release probability of different hippocampal synapses [59]. In parallel,  $A_1$ R activation also inhibits potassium conductances at the postsynaptic level, leading to neuronal hyperpolarization (reviewed in [55]). This latter effect is of uppermost importance to control the

bursting of neuronal firing, but has a minor importance for the control of synaptic transmission at lower frequencies of nerve stimulation (see [58]). However, it has been questioned whether the  $A_1$ R-mediated inhibition of glutamate release (which appears to be the predominant action of adenosine at lower frequencies of nerve stimulation) might be of relevance for the control of neuronal firing at higher frequencies of nerve stimulation (see [60]). The high density of  $A_1$ Rs in the post-synaptic density also anticipates an important role of adenosine in the control of signal integration at the post-synaptic level. Accordingly, the pioneering work of de Mendonça revealed that the tonic activation of  $A_1$ Rs controls the amplitude of synaptic plasticity in excitatory circuits (reviewed in [61]). This might result from the ability of  $A_1$ Rs to efficiently control NMDA receptors [62, 63] as well as post-synaptically located voltage-sensitive calcium channels [52, 63].

In contrast to these multiple actions of  $A_1$ Rs to inhibit neuronal function, our knowledge about the role of  $A_{2A}$ Rs in modulating neuronal activity is more limited. This is




Figure 2. Adenosine  $A_1$  and  $A_{2A}$  receptors ( $A_1$ R,  $A_{2A}$ R) can form dimers with different metabotropic receptors operated by other neurotransmitters. This opens the possibility that adenosine may operate hitherto unrecognised entities that may display novel pharmacological properties.

mainly because most of the studies have focused in the basal ganglia where  $A_{2A}$ Rs are by far more abundant because of their 'abnormal' large expression in the medium spiny neurons of the indirect pathway. Thus, the study of these  $A_{2A}$ Rs, which have a particular density and subcellular localization in this particular set of neurons, might not be representative of the more general role of  $A_{2A}$ Rs in the most regions of the brain. Outside the basal ganglia, the function that has mostly been ascribed to  $A_{2A}$ Rs is the control of neurotransmitter release, in accordance with the preponderant presynaptic localization of extra-striatal  $A_{2A}$ Rs (see [33]). As previously discussed (see the section "Subcellular localization of adenosine receptors"),  $A_{2A}$ Rs have been shown to facilitate the release of most neurotransmitter types (glutamate, GABA, glycine, acetylcholine, noradrenaline, serotonin) in different extra-striatal brain regions. Although it is also known that extra-striatal  $A_{2A}$ Rs are also located in the post-synaptic density (although with a density lower than in nerve terminals), only one report has so far described the ability of  $A_{2A}$ R activation to depolarise hippocampal neurons by a mechanism that remains to be unravelled [64].

In conclusion, in relation to the two main adenosine receptors in the brain, both seem to cause opposite effects on the release of excitatory neurotransmitters in the brain. In particular, in glutamatergic nerve terminals, it has been shown that  $A_1$  and  $A_{2A}$  receptors are co-located in a subset of these terminals in the hippocampus [65] and there is a functional interaction between these two adenosine receptors with opposite effects on glutamate release [32, 66]. Furthermore, extra-striatal  $A_{2A}$ Rs can also facilitate the release of some neurotransmitters that are not controlled by  $A_1$ Rs, like GABA or noradrenaline. Apart from these presynaptic effects,  $A_1$ Rs can also concur to inhibit neuronal activity by acting post-synaptically, both in distal dendrites (mainly at the post-synaptic density) as well as in proximal dendrites.

Whereas most available work provides a strong support for the effects of  $A_{2A}$ Rs in controlling neurotransmitter release and of  $A_1$ Rs to control both neurotransmitter release and neuronal excitability, it is important to also consider other more subtle or indirect mechanisms by which adenosine receptors might control neuronal function. One of the subtle effects of adenosine might be to fine-tune other systems controlling neurotransmitter release [67]. The work of Correia-de-Sá was instructive to understand the key role of  $A_{2A}$ Rs in resetting the modulatory systems able to come into play at the neuromuscular junction. Thus, the increased activation of  $A_{2A}$ Rs with increasing frequencies of nerve stimulation, can shut down the presynaptic nicotinic auto-facilitatory system [68], reset the muscarinic acetylcholine receptors [69] and allow the peptidergic presynaptic modulatory systems to come into play [70, 71]. Further work by Sebastião has extended this idea to the brain, where the peptidergic modulation of excitatory synaptic transmission in the hippocampus by G protein coupled receptors (operated by CGRP and VIP) is strictly dependent on the activation of  $A_{2A}$ Rs [72, 73]. More recent work has also found that the effects of BDNF on hippocampal synaptic trans-

mission are also abolished by blocking adenosine receptors [74] and  $A_{2A}$ Rs are able to trans-activate TrkB receptors [75]. This places  $A_{2A}$ Rs in a key position to shut on and off the important effects of neurotrophins in the brain. Figure 2 summarises the known modulatory systems whose efficiency is controlled by  $A_{2A}$ Rs and shows that receptors from all classes (metabotropic, ionotropic and catalytic) are under control by  $A_{2A}$ Rs. These results also prompt the need to always evaluate the status of adenosine receptors when studying any other presynaptic modulatory systems, since the functioning of most of the presynaptic neuromodulatory systems are in fact under a tight control by adenosine receptors (see [76]).

It should also be kept in mind that the effects of adenosine receptor activation are most likely not restricted to the direct control of neuronal activity. In fact, adenosine receptors are also located in other cell types in the brain (astrocytes, microglia, oligodendrocytes) that can indirectly influence neuronal activity. Figure 3 illustrates the localization of  $A_1$ Rs and  $A_{2A}$ Rs in different cell types and compartments in the brain, showing that adenosine is indeed well positioned to participate in neuron–glia communication. Astrocytes are equipped with all four types of adenosine receptors [77–82] that control astroglycolysis [83–84] and the release of different substances that can impact on neuronal activity [39, 85–88]. As occurs for the presynaptic control of neurotransmitter release, adenosine receptors in astrocytes also fine-tune the action of several other receptor systems in astrocytes, like metabotropic glutamate receptors [89, 90], histamine [91],  $\alpha$ 1-adrenergic receptors [92] and ATP P2Y receptors [93, 94]. One particular exciting action of adenosine receptor activation in glial cells is the control of the expression and release of cytokines [85, 95, 96]. Furthermore, adenosine receptors also control microglia reactivity [18, 97–99]. This prompts the hypothesis, initially raised by Schubert [100] that adenosine might play an important role in the control of neuro-inflammation, an issue that will be discussed later in more detail in the realm of the neuroprotective role of adenosine.

Finally, the last topic that should be considered when discussing the actions of adenosine in the brain is the ability of adenosine receptors to control metabolism. In fact, the activation of adenosine receptors can modify the primary metabolism of most cell types (see [1]) and this is also true for both neurons and astrocytes [101, 102] and in particular for the control of glycogen metabolism [51, 103, 104]. However, it still remains to be explored if this modulation of brain metabolism by adenosine receptors is implicated in the neuromodulatory or neuroprotective properties of adenosine or if it might be related with the trophic effects of purines (see [105]).

### Generation of extracellular adenosine

The general presentation of the different roles operated by adenosine in the brain clearly illustrates that adenosine

causes different and most often opposite actions by activating different receptors. Furthermore, it is now becoming clear that adenosine receptors causing opposite effects can be co-localised, at least in nerve terminals. Thus, it becomes of uppermost importance to understand how the differential activation of the different adenosine receptors can be effectively controlled to meet the needs of the system. One possibility would be that the different adenosine receptors might have different affinities for their endogenous ligand, i.e. adenosine. However, because it is not possible to completely eliminate endogenous adenosine (which is present in all biological preparations) one can only estimate rough affinities of the different adenosine receptors for adenosine. And most results suggest that the affinity of adenosine for A<sub>1</sub>Rs and A<sub>2A</sub>Rs is similar, in the low nanomolar range. Thus, one has to assume that there might be different ways of generating adenosine to activate either A<sub>1</sub>Rs or A<sub>2A</sub>Rs (reviewed in [1]). The correlate of this assumption is that one cannot define an "extracellular concentration of adenosine," but one should instead discuss an "extracellular gradient of adenosine."

The data obtained in hippocampal nerve terminals provides probably one of the few clear pictures of the extracellular metabolism of adenosine (which is particularly relevant given that the predominant role of adenosine is a presynaptic control of neurotransmitter release). Two main mechanisms have been identified in nerve terminals for the generation of extracellular adenosine: one is based on the release of adenosine as such through bi-directional non-concentrative (or equilibrative) nucleoside transporters [106]. In fact, inhibition of equilibrative nucleoside transporters can actually decrease the extracellular levels of adenosine in nerve terminals [107, 108], in accordance with a build-up of extracellular adenosine involving its release through equilibrative nucleoside transporters in this particular compartment of the brain. The second mechanism for the extracellular build-up of adenosine is its formation from released ATP, after its extracellular catabolism by ecto-nucleotidases (reviewed in [109]). Thus, ATP is stored in synaptic vesicles and nerve terminals release ATP on stimulation (reviewed in [110]). This release of ATP is larger the higher the frequency of nerve stimulation [111, 112] and the contribution of ATP-derived adenosine increases with increasing frequencies of nerve stimulation [112, 113]. In contrast, the contribution of adenosine released as such through equilibrative nucleoside transporters predominates at lower frequencies of nerve stimulation ([112]; see also [114]). Thus, in these hippocampal excitatory nerve terminals, there are two mechanisms responsible for the formation of extracellular adenosine and two adenosine receptors (A<sub>1</sub>Rs and A<sub>2A</sub>Rs) with opposite effects on glutamate release. And electrophysiological studies at these synapses revealed that the inhibitory effects of A<sub>1</sub>Rs clearly predominate at low frequencies of nerve stimulation, since blockade of A<sub>2A</sub>Rs, but not A<sub>1</sub>Rs, is devoid of effects [31, 115]. However, stimulation with burst of high frequencies reveals a tonic activation of A<sub>2A</sub>Rs [116] and inhibition of ecto-5'-nucleotidase blunts the tonic activation of A<sub>2A</sub>Rs [113, 117].

In conclusion, in this particular compartment of the brain, the available data provide a rationale to understand the differential activation of A<sub>1</sub>Rs and A<sub>2A</sub>Rs as a function of the intensity of functioning of the nerve terminals (reviewed in [1, 109]), which is based on the different relative contributions of two possible pathways for the build-up of extracellular adenosine, as summarised in Figure 4. This general mechanism of controlling A<sub>1</sub>R *versus* A<sub>2A</sub>R activation according to the levels of released ATP seems to be valid for hippocampal excitatory nerve terminals (reviewed in [1, 109]) and phrenic nerve endings [113]. However, it is important to stress that different types of nerve terminals are likely to have different organizations of extracellular adenosine metabolism and adenosine receptors as found, for instance, in cortical or hippocampal cholinergic nerve terminals (reviewed in [109]). One key aspect of the mechanistic explanation coupling the extracellular metabolism of released ATP with the preferential activation of A<sub>2A</sub>Rs is the proximal localization of ecto-5'-nucleotidase (responsible for the formation of ATP-derived adenosine) and A<sub>2A</sub>Rs. This has, so far, not been directly demonstrated to occur in hippocampal nerve terminals. However, it is striking to note that several physiological [117, 118] and pathological situations [119, 120] cause a parallel increase of the activity of ecto-5'-nucleotidase and of the density of A<sub>2A</sub>Rs, in contrast to A<sub>1</sub>Rs. Furthermore, in different models, it has been shown that noxious stimuli cause a parallel increase of the expression of ecto-5'-nucleotidase and of A<sub>2A</sub>Rs [121–123], strongly supporting the view that these two molecules are tightly interconnected.

In more integrated brain preparations, the relation between A<sub>1</sub>R and A<sub>2A</sub>R activation is less well defined. Here, it is unlikely that it might be the extracellular metabolism of adenosine that governs the relative activation of A<sub>1</sub>Rs and A<sub>2A</sub>Rs, because there is scarce evidence to support the co-localization of these two receptors outside excitatory nerve terminals. Furthermore, the source of extracellular adenosine is less well defined in more integrated brain preparations. Thus, most cell types and compartments in the brain are equipped with equilibrative nucleoside transporters. However, in integrated brain preparations, the inhibition or blockade of equilibrative nucleoside transporters causes an *increase* rather than a *decrease* of extracellular adenosine (reviewed in [124]). This means that the role of nucleoside transporters is to clear-up adenosine rather than to promote its release. It is now well accepted that all cell types release ATP, namely, neurons, astrocytes or microglia cells, by mechanisms that remain controversial [125]. Likewise, all cell types are endowed with ecto-nucleotidases, forming an efficient enzymatic pathway to convert ATP into adenosine (reviewed in [126]). However, in most integrated brain preparations (and in contrast to nerve terminals), the prototypical inhibitor of ecto-5'-nucleotidase,  $\alpha,\beta$ -methylene ADP, fails to modify the extracellular levels of adenosine (reviewed in [124]). It is possible that in more integrated preparations, the conversion of adenine nucleotides into adenosine cannot be effectively prevented. In





Figure 3. All cell types and sub-cellular compartments in the brain are endowed with different relative proportions (indicated by the relative size of the circles) of adenosine  $A_1$  and  $A_{2A}$  receptors ( $A_1R$ ,  $A_{2A}R$ ) that fulfil different roles according to their localization. Since all the represented compartments can also release both ATP and adenosine and are endowed with ecto-nucleotidases to convert extracellular ATP into adenosine, this nucleoside is ideally positioned to mediate all conceivable forms of neuron–glia communication. This scheme also illustrates that the effects of adenosine in the brain might always result from a balanced modulation of all cell types and compartments in the brain. COX, cyclooxygenase; GTL, glutamate transporter; Glu, glutamate; NGF, nerve growth factor; VSCCs, voltage-sensitive calcium channels.


fact,  $\alpha,\beta$ -methylene ADP is a competitive inhibitor of ecto-5'-nucleotidase, but does not affect other ecto-enzymes able to metabolise AMP (reviewed in [126]). It should also be kept in mind that the ecto-nucleotidase system is a notable efficient system, probably organised in a channelled manner [127] and able to generate adenosine to act on its receptors in a few milliseconds [128], a time course faster than the  $K_{cat}$  of soluble enzymes. Thus, in more integrated preparations, either the concentration of  $\alpha,\beta$ -methylene ADP fails to equilibrate with ecto-5'-nucleotidase or enzymes other than ecto-5'-nucleotidase are mostly responsible for the formation of extracellular adenosine or there are other (still unknown) pathways of extracellular adenosine formation that are still to be identified. Note that in purified nerve terminals, which only account for 1%–2% of the volume of more integrated preparations [129], spatial restraints are decreased and it is the only preparation where it has been demonstrated that ecto-5'-nucleotidase

was the predominant enzymatic activity responsible for the formation of extracellular adenosine from adenine nucleotides [130]. Thus, in nerve terminals,  $\alpha,\beta$ -methylene ADP is able to decrease the formation of extracellular adenosine [107, 108, 112, 117, 118].

In conclusion, in more integrated brain preparations, it appears that the role of equilibrative nucleoside transporters is to clear-up adenosine. Hence, the formation of extracellular adenosine should result from the extracellular metab-



Low frequency – acute stress



High frequency – chronic stress




Figure 4. Schematic representation of the ability of the extracellular metabolism of adenosine (and ATP) to determine which adenosine receptor-mediated effect will be preponderant in glutamatergic nerve terminals of the rat hippocampus. Thus, at lower frequencies of nerve stimulation, there is a lower release of ATP, which will form low amounts of adenosine allowing the nucleoside transporters to contribute for the accumulation of extracellular adenosine, favouring the activation of  $A_1$  receptors. At higher frequencies of stimulation, the release of ATP is disproportional larger, the extracellular levels of adenosine will be essentially derived from ATP (after its catabolism by ecto-nucleotidases), leading to a preferential activation of  $A_{2A}$  receptors that are in close proximity of ecto-5'-nucleotidase. ADO, adenosine; AK, adenosine kinase; NT, neurotransmitter (in this case, glutamate); NTPDase, ecto-nucleotidases able to convert ATP and/or ADP into AMP; 5'-N, ecto-5'-nucleotidase; T, equilibrative nucleoside transporters.

olism of released adenine nucleotides, but direct evidence for this is lacking. Extracellular ATP is the strongest candidate to act as a primary source of adenosine since it is released in a controlled manner from neurons (reviewed in [110]) and from astrocytes [131–141] as well as from activated microglia [142]. It has also been proposed that cAMP could be released from neurons [143], but its contribution is at best limited [144]. Clearly further work is required to elucidate the pathways of generation of extracellular adenosine in the brain, which is a pre-requisite to understand the dynamics of activation of adenosine receptors in different physio-pathological conditions.

### **Modification of adenosine metabolism on stressful conditions**

When considering the relevance of adenosine in the realm of neuroprotection, it is most important to first consider the consequences of noxious stimuli on the extracellular metabolism of adenosine. This will allow gaining insight on the neuroprotective role of endogenous adenosine and it is also instructive to understand if it makes sense to pharmacologically manipulate the effects mediated by adenosine receptors when their tonic activation might be dramatically modified.

The energy charge is one of the fundamental parameters (together with the redox status) to define the status of the primary metabolism of cells. Hence, it is one of the earliest parameter to be re-adjusted by any stressful stimuli in all cell types. Based on the tight relation between the levels of adenosine and the energy charge, it is expectable that the tissue levels of adenosine will be modified by noxious stimuli. In fact, the intracellular concentration of ATP is in the range of 3–10 mM, i.e. about 100,000 times greater than that of adenosine (between 10 and 50 nM). Thus, slight changes in the concentration of ATP will cause several-fold changes in the intracellular concentration of adenosine (discussed in [1]). Therefore, it is not surprising that stimuli ranging from increased neuronal firing to hypoxia, ischemia or cell poisoning will cause increases in the extracellular levels of adenosine (reviewed in [124]; [1]). However, the mechanism responsible for coupling the expected increase in the intracellular levels of adenosine and the observed increased levels of extracellular adenosine is still not clear.

The simplest explanation would be that the adenosine formed intracellularly would be released through equilibrative nucleoside transporters thus leading to increased levels of extracellular adenosine. According to this scenario, there is a good correlation between the graded intensity of the noxious stimuli applied, the drop in energy charge of the studied brain tissue and the extracellular levels of adenosine (e.g., [145, 146]). Also, blockade of the intracellular enzymatic pathways responsible for the consumption of intracellular adenosine (mainly adenosine deaminase and adenosine kinase) increase the extracellular levels of adenosine under different noxious conditions in brain preparations (e.g., [147, 148]; reviewed in [124]).

However, the inhibition of equilibrative nucleoside transporters increases the extracellular levels of adenosine. This tells us that the role of equilibrative nucleoside transporters is mostly to take up rather than to release adenosine, as occurs during non-stressful conditions (reviewed in [1]; [124]). The obvious alternative is that the formation of extracellular adenosine should result from the extracellular catabolism of released adenine nucleotides triggered by noxious stimuli. Some few studies have reported a release of ATP as such during stressful stimulation of brain preparations [149–153]. Also, both axonal depolarization and increased glutamate levels, both of which are hallmarks of potential neurotoxic conditions, are effective triggers of ATP release [154–156]. And, although it remains to be tested if this stress-induced ATP release contributes for the extracellular build-up of adenosine, it is interesting to note that there is an up-regulation of ecto-nucleotidases upon noxious brain conditions [120, 157–159].

This presentation and discussion of the data available on purine release during noxious brain conditions clearly tells us how little is known about the pathways of generation of extracellular adenosine in stressful conditions. In fact, neither the pathways leading to the build-up of extracellular adenosine nor the major cell type (or sub-cellular compartments) contributing for this elevation of the extracellular levels of adenosine caused by noxious stimuli have been experimentally tackled.

In spite of our ignorance on how extracellular adenosine is formed, it is never the less evident that noxious stimuli trigger a robust increase in the extracellular levels of adenosine that reaches micromolar concentrations in the extracellular fluid of stressed brain preparations (reviewed in [124]). Given that the affinity for adenosine of the most abundant adenosine receptors ( $A_1$ Rs and  $A_{2A}$ Rs) is in the low nanomolar range, the obvious question that pops up is whether these increased levels of endogenous adenosine are enough to saturate  $A_1$ Rs and  $A_{2A}$ Rs. In fact, if this was to occur, it would make little sense to devise any therapeutic neuroprotective strategy based on the use of agonists of adenosine receptors. This does not appear to be the case since inhibition of the key enzymatic activities thought to control the availability of adenosine still potentiates the neuroprotective effects of endogenous adenosine. In fact, inhibition of adenosine kinase is strongly neuroprotective in different animal model of brain injury [160–166], and some, but not all studies (see [167, 168]), also found that inhibitors of adenosine deaminase were neuroprotective [169, 170]. This clearly indicates that it is justified to invest a greater effort into understanding the changes of the metabolism of adenosine caused by noxious stimulation.

### **Acute $A_1$ receptor activation increases the threshold for acute neurodegeneration**

When considering which adenosine receptor plays a major role in affording neuroprotection in the brain, the strongest



candidate is obviously the A<sub>1</sub>R. This is because A<sub>1</sub>Rs have a major inhibitory effect on synaptic transmission and neuronal excitability (see “Modulatory roles of adenosine”) and also because they are, by far, the most abundant adenosine receptor subtype in the brain. And, in fact, a diversity of studies in different brain preparations of different species using different noxious stimuli, consistently found that the acute activation of inhibitory A<sub>1</sub>Rs is neuroprotective (elegantly reviewed in [171]). Thus, in isolated neurons and in brain slices, A<sub>1</sub>R activation reduces damage to neurons, whereas A<sub>1</sub>R antagonists potentiate damage (reviewed in [171–174]). Likewise, in whole animals subject to ischemia or other type of brain noxious stimuli (e.g., epileptic models, trauma, exposure to excitotoxins), it is also concluded that the acute activation of A<sub>1</sub>Rs is neuroprotective, whereas A<sub>1</sub>R antagonists potentiate damage (reviewed in [171–176]).

In conclusion, the data available are notably consistent in establishing a neuroprotective role for A<sub>1</sub>R acute activation in noxious brain conditions in adult animals. Likewise, the worsening effect caused by A<sub>1</sub>R antagonists, as well as the beneficial effect caused by enhancing the extracellular levels of adenosine (reviewed in [171–174]) or using allosteric enhancers of A<sub>1</sub>Rs [177], also indicates that the tonic activation of A<sub>1</sub>Rs is an endogenous neuroprotective system in stressful brain situations.

However, the therapeutic interest of A<sub>1</sub>R agonists has several limitations that hamper its usefulness as novel neuroprotective drugs. The first major drawback is due to the profound cardiovascular effects of A<sub>1</sub>R agonists (e.g., [178, 179]), which are most worrying because A<sub>1</sub>R agonists have a poor brain permeability [180, 181]. The second limitation is related to the short ‘window of opportunity’ of A<sub>1</sub>R agonists, which is limited to a few hours, at most, after the initiation of the brain insult (reviewed in [171, 173, 174]; but see [182]). This is aggravated by the fact that is not conceivable to administer A<sub>1</sub>R agonists chronically (as a preventive strategy) because it causes an effect inversion, i.e. chronic A<sub>1</sub>R stimulation actually exacerbates neuronal loss caused by noxious brain stimulation (reviewed in [183]). Finally, the last major limitation to develop A<sub>1</sub>R agonists as neuroprotective drugs is the observation that the effect of A<sub>1</sub>R activation desensitize in chronic stressful brain conditions, as shall be discussed in more detail in “Long-term desensitization of A<sub>1</sub> receptors and up-regulation of A<sub>2A</sub> receptors by chronic noxious conditions.”

In conclusion, it appears that the activation of A<sub>1</sub>Rs is an endogenous neuroprotective system, but its usefulness is limited to *acute* noxious brain conditions, i.e., to control the onset or enhance the threshold of neuronal damage.

### **Long-term desensitization of A<sub>1</sub> receptors and up-regulation of A<sub>2A</sub> receptors by chronic noxious conditions**

Adenosine A<sub>1</sub>Rs belong to the G protein-coupled receptor family but, unlike most in their family, A<sub>1</sub>Rs have a long

half-life (e.g., [184]) and seem to be resilient to desensitization [185]. In fact, several works suggest that neuronal A<sub>1</sub>R desensitization occurs in large time frames (12–24 h) of exposure to exogenously added A<sub>1</sub>R agonists *in vitro* (e.g., [184, 186, 187]) as well as *in vivo* (e.g., [188, 189]). The time course of desensitization of A<sub>1</sub>Rs is particularly critical to understand if adenosine maintains its neuroprotective efficiency in chronic noxious brain situations.

In animal models of epilepsy as well as in patients with temporal lobe epilepsy, i.e., in situations causing a long-lasting enhanced release of adenosine (e.g., [190–192]), there is a long-term decrease in the density of A<sub>1</sub>Rs in different brain regions [120, 193–195], which is also observed in patients with mesial sclerosis ([196]; but see [197]). This decreased density of A<sub>1</sub>Rs is in general agreement with the development of tolerance in relation to the anti-convulsive effects of A<sub>1</sub> receptor agonists [198, 199] that is accompanied by a reduced potency of A<sub>1</sub>R agonists [120]. In other chronic neurodegenerative conditions, such as Alzheimer’s disease, the density of A<sub>1</sub>Rs is also reduced ([206, 397, 398]; but see [207]). Likewise, several studies showed that short periods of brain ischemia, which also trigger a robust increase in the extracellular levels of adenosine ([121]; reviewed in [172]), produce a long-lasting decrease in the density of A<sub>1</sub>Rs in several brain regions (e.g., [200–202]). Again, this hypoxia-induced homologous desensitization of A<sub>1</sub>Rs [203] is accompanied by a loss of efficiency of A<sub>1</sub>R agonists when applied more than one hour after the hypoxia period (reviewed in [171, 173, 174]; but see [182]). This homologous desensitization of A<sub>1</sub>Rs has also been documented in other situations which trigger the release of adenosine. Thus, the implementation of long-term potentiation, which triggers a robust release of adenosine (see [112]), also decreases the efficiency of A<sub>1</sub>R modulation of synaptic transmission [204, 205].

In conclusion, several physio-pathological conditions able to generate endogenous extracellular adenosine, cause a long-term down-regulation of A<sub>1</sub>Rs that contributes to hamper the neuroprotective effectiveness of the A<sub>1</sub>R system in chronic noxious brain conditions. This is in agreement with the idea that the activation of A<sub>1</sub>Rs is important to control the *acute onset* of neuronal dysfunction and/or neurodegeneration, but that these A<sub>1</sub>Rs suffer a long-term desensitization making the A<sub>1</sub>R system less appealing as a target for the development of neuroprotective agents aimed at interfering with *long-term chronic* noxious brain conditions.

Considerably fewer studies have been performed to investigate the long-term effect of noxious stimuli to the density and efficiency of A<sub>2A</sub>Rs in the brain. Most studies have focused on the striatum, where both the density and the role of A<sub>2A</sub>Rs are biased by their particular localization with high density in a particular subset of neurons, the medium spiny neurons of the indirect pathway. Interestingly, in clear contrast with what occurs for A<sub>1</sub>Rs, chronic stressful stimuli directed to the basal ganglia cause an increased expression and density of A<sub>2A</sub>Rs, as observed in animal models of Parkinson’s disease (e.g., [208, 209]) and

in Parkinsonian patients ([210]; see also [211, 212]). It is also possible that the expression of A<sub>2A</sub>Rs might also increase in animal models and patients with Huntington's disease, since the expression of A<sub>2A</sub>Rs is increased in neurons over-expressing huntingtin [213]. However, the major loss of medium spiny neurons in this condition may mask the increased density of A<sub>2A</sub>Rs in the remaining viable neurons [211, 214, 215]. Interestingly, this idea that brain A<sub>2A</sub>Rs might be up-regulated by noxious stimuli was most evident in a recent study focusing on extra-striatal regions. It was observed that convulsive behaviour caused a long-term robust enhancement of the density of cortical A<sub>2A</sub>Rs, which contrasted with the decreased density of cortical A<sub>1</sub>Rs [195]. Likewise, in brain sections from patients with Alzheimer's disease, a greater density of A<sub>2A</sub>Rs was also observed, which was reported to be confined to microglia processes [207]. This is in agreement with the recently reported increase in the density of A<sub>2A</sub>Rs in activated microglia cells [216] and with the ability of cytokines to up-regulate A<sub>2A</sub>Rs [217]. This increase in A<sub>2A</sub>R density and efficiency is also observed in other cell models systems, like PC12 cells (see [121, 218]) or activated lymphoid cells [219–223]. Finally, an up-regulation of A<sub>2A</sub>Rs was also reported in schizophrenic patients [224].

In conclusion, the balance between A<sub>1</sub>Rs and A<sub>2A</sub>Rs in the brain appears to be modified by stressful stimuli. In fact, stressful stimuli cause a decrease of A<sub>1</sub>R density and efficiency whereas there is an increased expression and density of A<sub>2A</sub>Rs. This confirms the idea that the neuroprotective effect of A<sub>1</sub>Rs is probably most relevant at the onset of brain damage, whereas A<sub>2A</sub>Rs might come into play at latter stages of brain damage and in particular in chronic noxious brain conditions that are characteristic of neurodegenerative diseases.

### A<sub>2A</sub> receptor blockade confers robust neuroprotection

The presentation of the available evidence to suggest an up-regulation of A<sub>2A</sub>Rs by noxious stimuli makes it logical to conceive that the manipulation of the activity of this receptor might affect the outcome of brain damage. But the first report by Phillis' group that a non-selective A<sub>2A</sub>R antagonist (CGS 15943) attenuated cerebral ischemic injury [225], in contrast to A<sub>1</sub>R antagonists [226], appeared as a serendipitous observation. Similar observations were made by von Lubitz in a similar gerbil model of brain ischemia [227]. However, this concept of A<sub>2A</sub>R blockade as a neuroprotective strategy was difficult to understand at the time and consequently was not widely accepted until the group of Ongini and the group of Chen demonstrated that both the pharmacological blockade of A<sub>2A</sub>Rs with a selective antagonist (SCH 582610) [228] as well as the genetic inactivation of A<sub>2A</sub>Rs (using A<sub>2A</sub>R knockout mice) [229] conferred a robust neuroprotection in animal models of focal ischemia.

In the last three years, numerous studies by different groups using different noxious brain stimuli have systematically confirmed this ability of A<sub>2A</sub>R blockade to confer

robust neuroprotection (reviewed in Table 1). Interestingly, this neuroprotection afforded by A<sub>2A</sub>R blockade was more robust in cortical regions than in the basal ganglia, where these A<sub>2A</sub>Rs are considerably more abundant [228, 229, 231]. This emphasises again that the 'abnormal' high density of A<sub>2A</sub>Rs in striatal medium spiny neurons of the indirect pathway fulfils a very particular role in the control of striatal circuitry and that our knowledge about striatal A<sub>2A</sub>Rs should not be extrapolate to understand the general role of A<sub>2A</sub>Rs in the brain. Nevertheless, although A<sub>2A</sub>R blockade is particularly effective in preventing cortical and hippocampal damage [225, 229, 231–237], it is also effective in attenuating striatal damage following brain ischemia [229, 231], exposure to quinolinic acid [230, 238], 3-nitropropionic acid [239, 240], malonate [241] or MPTP [242, 243].

One particular interesting aspect related with the neuroprotection derived from the blockade of A<sub>2A</sub>Rs is that the effects of A<sub>2A</sub>Rs do not seem to desensitize with prolonged administration of A<sub>2A</sub>R antagonists [244, 245]. This contrasts with the neuroprotection based on the activation of A<sub>1</sub>Rs, which desensitises over time (see "Long-term desensitization of A<sub>1</sub> receptors and up-regulation of A<sub>2A</sub> receptors by chronic noxious conditions"). In particular, long-term exposure of caffeine leads to a rapid A<sub>1</sub>R desensitization but maintenance of A<sub>2A</sub>R-mediated responses [246]. Thus, the maintenance over long periods of the central effects of A<sub>2A</sub>R antagonists, probably related to the stress-induced up-regulation of A<sub>2A</sub>Rs (see "Long-term desensitization of A<sub>1</sub> receptors and up-regulation of A<sub>2A</sub> receptors by chronic noxious conditions"), makes this receptor an attractive target for prolonged manipulation of brain injury. The use of A<sub>2A</sub>R antagonists as novel neuroprotective drugs is also favoured by their beneficial pharmacokinetic profile. In fact, the doses of A<sub>2A</sub>R antagonists that afford neuroprotection are considerably lower than these producing peripheral effects, namely cardiovascular effects (see [247, 248]). In fact, the neuroprotective properties of A<sub>2A</sub>R antagonists are lost on increasing their dosage [237–240], but it is still unclear if this is related to an increased contribution of peripheral effects, to a differential blockade of different populations of A<sub>2A</sub>Rs or to a loss of selectivity of the currently available A<sub>2A</sub>R antagonists. Finally, the neuroprotective effective doses of A<sub>2A</sub>R antagonists are also devoid of other measurable central effects, which is in accordance with the lack of evident secondary effects in the on-going clinical trials with A<sub>2A</sub>R antagonists (unpublished results). In conclusion, the lack of peripheral or other evident central effects together with the maintenance over time of A<sub>2A</sub>R-mediated responses make A<sub>2A</sub>Rs particular interesting targets to develop novel and effective neuroprotective drugs.

One important aspect that remains to be unravelled is the mechanism(s) by which A<sub>2A</sub>R blockade affords such robust neuroprotection. This is particularly intriguing given that cortical and hippocampal A<sub>2A</sub>Rs have a low abundance (in the range of 20 fmol/mg of protein compared to a 50-times greater density of A<sub>1</sub>Rs; [7]) and the amplitude of the effect resulting from A<sub>2A</sub>R activation is discrete, especially when

evaluating neuronal activity. Probably because several groups reported an ability of A<sub>2A</sub>Rs to control the release of glutamate both in the cerebral cortex [249–251], hippocampus [31, 32, 252] and striatum [26, 230, 253–257], the hypothesis that the A<sub>2A</sub>R-mediated control of glutamate release might be the explanation for the neuroprotective effects of A<sub>2A</sub>Rs became popular [238, 258]. Indeed, some studies reported that A<sub>2A</sub>R activation was involved in enhancing the extracellular levels of glutamate triggered by noxious stimuli [231, 238, 249, 251]. However, in more simplified models of neuronal dysfunction, it was not possible to confirm that the presynaptic modulation of glutamate release by A<sub>2A</sub>Rs was related to their control of neuronal damage. In fact, when studying hypoxia- or ischemia-induced depression of synaptic transmission, where the presynaptic control of glutamate release is related to the post-hypoxic recovery of synaptic transmission (see [259]), blockade of A<sub>2A</sub>Rs is essentially devoid of effects [259, 260]. An interesting alternative to reconcile the control of extracellular glutamate levels by A<sub>2A</sub>Rs with the neuroprotective role of A<sub>2A</sub>R blockade would be a control by A<sub>2A</sub>Rs of the release and clearance of glutamate by astrocytes. Thus, A<sub>2A</sub>R activation can inhibit glutamate transport into astrocytes [261], in particular GLT-1 [40] and enhance the release of glutamate from astrocytes [39, 40]. However, strong arguments have been provided to support the view that the role of glutamate transporters during stressful stimuli is to contribute for the extracellular build-up of glutamate rather than for its removal (see, e.g., [262]). In conclusion, it remains to be determined what

might be the contribution of the A<sub>2A</sub>R modulation of astrocytic glutamate transporters in the realm of the neuroprotection afforded by A<sub>2A</sub>R antagonists in noxious brain conditions.

It is also important to consider that A<sub>2A</sub>R antagonists are effective in preventing neurotoxicity in isolated neurons in culture. In fact, both caffeine and antagonists of A<sub>2A</sub>Rs (SCH 58261 or ZM 241385) effectively prevent the neurotoxicity induced by exposure of cerebellar [263] or hippocampal neurons [264] to the fragment 25–35, 1–40 or 1–42 of  $\beta$ -amyloid protein (A $\beta$ ), a putative causative factor of Alzheimer's disease [265]. And there is no evidence to suggest that A $\beta$  enhances glutamate release, since the effect of A $\beta$  is the opposite, i.e. to depress glutamatergic transmission (reviewed in [266]). Thus, one has to assume that A<sub>2A</sub>Rs might have direct effects on neurons to control their susceptibility to neurotoxic stimuli. The possible control by A<sub>2A</sub>Rs of one the receptor systems most frequently involved in neurodegeneration, the NMDA receptor, does not appear to be a likely candidate. In fact, it has been shown that A<sub>2A</sub>R activation actually *inhibits* NMDA receptors in striatal neurons [267–269] and A<sub>2A</sub>R blockade *increased* NMDA-dependent neurotoxicity in the hippocampus [270]. Alternatively, A<sub>2A</sub>Rs might control the apoptotic machinery in neurons and other cell types in the brain (see [264]), in a manner similar to the control by A<sub>2A</sub>Rs of apoptosis in PC12 cells [271–273] or in neutrophils [274–276].

Another hypothesis, first advanced by Schubert to understand adenosine neuroprotection would be the possi-

Table 1. Neuroprotective effects afforded by A<sub>2A</sub>R blockade/inactivation in *in vivo* models of adult brain toxicity.

| Experimental model              | Manipulation                  | Effect                                | Reference |
|---------------------------------|-------------------------------|---------------------------------------|-----------|
| Global ischemia, gerbil         | CGS 15943 0.1 mg/kg i.p.      | Protection (HIP cell loss)            | [225]     |
| Global ischemia, gerbil         | CSC 0.1 mg/kg i.p.            | Protection (HIP cell loss)            | [226]     |
| Forebrain ischemia, gerbil      | CSC 1 mg/kg i.p.              | Protection (HIP cell loss)            | [227]     |
| Forebrain ischemia, rat         | SCH58261 0.01 mg/kg i.p.      | Protection (CTX infarct vol.)         | [228]     |
| Forebrain ischemia, mouse       | A <sub>2A</sub> R knockout    | Protection (CTX, STR infarct vol.)    | [229]     |
| Forebrain ischemia, rat         | SCH58261 0.01 mg/kg i.p.      | Protection (CTX, STR infarct vol.)    | [231]     |
| Forebrain ischemia, rat         | SCH58261 0.01 mg/kg i.v.      | Protection (CTX <i>c-fos</i> density) | [233]     |
| Ischemia + hyperglycemia, rat   | ZM241385 1 mg/kg i.p.         | Protection (HIP cell loss)            | [234]     |
| KA intra-HIP, rat               | ZM241385 2.5 pmol intra-HIP   | Protection (HIP cell loss)            | [235]     |
| KA i.c.v., mouse                | DMPX 20 $\mu$ g i.c.v.        | Protection (HIP cell loss)            | [236]     |
| KA i.p., rat                    | SCH58261 0.01–0.05 mg/kg i.p. | Protection (HIP cell damage)          | [284]     |
| LPS i.c.v., rat                 | SCH58261 5 pmol, i.c.v.       | Protection (HIP LTP)                  | [285]     |
| QA + X/XO intra-HIP, rat        | ZM421385 25 pmol intra-HIP    | Protection (HIP cell loss)            | [232]     |
|                                 | SCH58261 50 pmol intra-HIP    |                                       |           |
|                                 | CSC 100 pmol intra-HIP        |                                       |           |
| QA intra-STR, rat               | DMPX0.2 $\mu$ g intra-STR     | Protection (CTX EEG)                  | [237]     |
| QA intra-STR, rat               | SCH58261 0.01 mg/kg i.p.      | Protection (CTX EEG, STR glycosis)    | [238]     |
| 3-NP i.p., rat, mouse           | A <sub>2A</sub> R knockout    | Protection (STR lesion vol.)          | [239]     |
|                                 | MSX-3 5 mg/kg i.p.            |                                       |           |
| 3-NP i.p., mouse                | A <sub>2A</sub> R knockout    | Protection (STR lesion vol.)          | [240]     |
|                                 | CSC 5–20 mg/kg i.p.           |                                       |           |
| Malonate intra-STR, rat, mouse  | DMPX 5 mg/kg i.p.             | Protection (STR TH, DA levels)        | [241]     |
| MPTP i.p., mouse                | A <sub>2A</sub> R knockout    | Protection (STR DAT, DA levels)       | [242]     |
| MPTP i.p., rat 6-OHDA intra-STR | KW6002 1–10 mg/kg p.o.        | Protection (STR DAT, DA levels)       | [243]     |

CTX, cortical; DA, dopamine; DAT, dopamine transporters; EEG, electroencephalography; i.c.v., intracerebroventricular; i.p., intraperitoneal; i.v., intravenous; HIP, hippocampal; KA, kainate; KO, knockout; LPS, lipopolysaccharide; LTP, long-term potentiation; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3-NP, 3-nitropropionic acid; p.o., oral administration; QA, quinolinic acid; STR, striatal; TH, tyrosine hydroxylase; vol., volume; X, xanthine; XO, xanthine oxidase.

bility that A<sub>2A</sub>Rs might control the process of neuro-inflammation [277]. The process of neuro-inflammation is known to contribute for the spreading of neuronal damage in different noxious brain conditions and particular attention is currently focused on the therapeutic possibilities of controlling neuro-inflammation as a strategy to attenuate the neurological consequences of neurodegenerative diseases (reviewed in [278, 279]). Since the brain is not subject to the actions of the inflammatory system under physiological conditions (immune privilege of the brain; reviewed in [280]), it is generally accepted that the initial trigger of neuro-inflammation is dependent on the recruitment and activation of microglia cells, which are brain-resident (reviewed in [281]). Accordingly, activated microglia are found in most brain noxious conditions such as ischemia, trauma, brain infections, epilepsy, Parkinson's, Alzheimer's or Huntington's disease (reviewed in [278]; [279, 282]) and activated microglia are even considered one of the most sensitive sensors for pathological events in the brain (see [283]). Some evidences suggest that A<sub>2A</sub>Rs can control the detrimental neuronal consequences associated with neuro-inflammation. Blockade of A<sub>2A</sub>Rs completely prevented the recruitment of activated microglia to the CA3 region of the hippocampus in rats injected with kainate [236]. However, this might either be due to a direct effect of A<sub>2A</sub>Rs known to be present in microglia cells [41, 42, 216] or because A<sub>2A</sub>R antagonists control the evolution of the severity of convulsion and associated neurotoxicity triggered by cumulative sub-threshold amygdala kindling or by kainate injection [284], which pre-date microglia recruitment. It was also recently shown that an A<sub>2A</sub>R antagonist (SCH 58261) can prevent the hippocampal neuronal dysfunction and neurotoxicity triggered by the direct administration of lipopolysaccharide (LPS) [285], a potent inflammatory trigger and activator of microglia cells (see e.g., [286, 287]). Interestingly, SCH 58261 also attenuated the LPS-induced neuro-inflammation, as evaluated by the abolishment of LPS-induced increase in interleukin 1 $\beta$  levels and the recruitment of activated microglia [285]. This shows that A<sub>2A</sub>R blockade effectively control neuro-inflammation and the neuronal dysfunction and damage resulting from a neuro-inflammatory status in the brain. However, it does not allow stating that microglial A<sub>2A</sub>Rs play a key role in controlling the involvement of A<sub>2A</sub>Rs in neuronal damage. In fact, studies with cultured cells showed that adenosine can directly attenuate neuronal damage caused by administration to neurons of medium from activated microglia cultures [98]. The development of a neuro-inflammatory process depends not only on microglia activation, but also on the participation of astrocytes (e.g., [288]) and neurons (e.g., [289]), as well as on the involvement of infiltrating myeloid cells (see [282, 290, 291]). Interestingly, a recent elegant study by the group of Jiang-Fan Chen showed that brain resident A<sub>2A</sub>Rs might only play a minor role in controlling neurodegeneration, at least in an animal model of focal ischemia [292], which causes a major disturbance of the blood-brain barrier with the easier invasion of circulating myeloid cells (reviewed in [293]). By comparing the infarcted area in the cerebral

cortex of  $\gamma$ -irradiated wild-type mice receiving a bone marrow transplant from A<sub>2A</sub>R knockout mice and  $\gamma$ -irradiated A<sub>2A</sub>R knockout mice transplanted with bone marrow from wild-type mice, they found that a superior neuroprotection was observed in the second group (i.e., which possessed A<sub>2A</sub>Rs in myeloid cells but not in the brain). It remains to be tested if A<sub>2A</sub>R in myeloid cells also play a key role in other brain noxious conditions where the infiltration of these cells into the brain is less well documented.

This proposal that the effect of A<sub>2A</sub>Rs in myeloid cells is most important for the role of A<sub>2A</sub>Rs in the control of brain damage is surprising based on the well established robust role of adenosine in *attenuating* (rather than *exacerbating*) inflammation in the periphery ([294]; reviewed in [295, 296]). In fact, adenosine is a potent anti-inflammatory agent with A<sub>2A</sub>Rs triggering "OFF" signals in activated immune cells, which constitutes one of the most fundamental and immediate tissue-protecting mechanisms (reviewed in [295, 296]). A<sub>2A</sub>R agonists were even named "the most potent anti-inflammatory drug known to mankind." Accordingly, activation of A<sub>2A</sub>Rs has been shown to confer a robust protection against tissue damage from ischemia-reperfusion injury in different organ such as heart [297–299], blood vessels [300], kidney [301, 302], liver [303, 304], lung [305, 306], joints [307], skin [308, 309], and even in the spinal cord [310, 311] and in the brain following hemorrhage [312] or acute infection [313]. Thus, it is the activation (rather the blockade) of A<sub>2A</sub>Rs that confers protection against damage triggered by inflammation in peripheral tissues, precisely the opposite of what is observed in the damaged adult brain. Moreover, A<sub>2A</sub>R blockade actually exacerbates tissue damage involving inflammatory reactions in the periphery (reviewed in [295, 296]), instead of the tissue protection, as observed in noxious brain conditions. Furthermore, all studies available indicate that the activation of A<sub>2A</sub>Rs inhibits the release of pro-inflammatory cytokines from inflammatory cells, such as macrophages (e.g., [223, 314–316]), dendritic cells [220, 221], monocytes [317–319] or T cells [320, 321]. This latter cell type, in particular CD4<sup>+</sup> T cells, are most relevant since it was recently shown that the key role of A<sub>2A</sub>Rs in attenuating peripheral tissue damage from ischemia-reperfusion injury is due to the activation of A<sub>2A</sub>Rs in CD4<sup>+</sup> T cells [322]. Since the depletion of CD4<sup>+</sup>-CD25<sup>+</sup> regulatory T cells has been shown to promote survival of neurons after brain insults [323], in a manner regulated by metabotropic receptors such as dopamine D<sub>1</sub> receptors [324], it would be interesting to test if A<sub>2A</sub>Rs might affect this particular population of T cells to control brain injury. However, the urgent need remains to provide a logical explanation for the fundamentally opposite effects of A<sub>2A</sub>Rs in cell death involving inflammatory reactions in the brain and in the periphery.

In conclusion, there are currently five concurring hypothesis to explain the robust neuroprotective effects afforded by A<sub>2A</sub> receptors in noxious brain conditions in adult animals: (1) presynaptic control of glutamate release; (2) control of astrocytosis and of glutamate uptake and re-

lease by astrocytes; (3) direct control of neuronal viability by interference with pathways of cell death; (4) control of microglia reactivity; (5) control of the reactivity of infiltrating lymphoid cells. As discussed, all these hypotheses have pitfalls that limit their acceptance. Most likely, it may be that different conjunctions of these mechanisms might come into play according to the type of insult, since different insults are likely to operate different demises of neuronal damage.

### Therapeutic neuroprotective potential based on adenosine in the adult brain

The results discussed so far allow to draw a general picture of the role of adenosine in the control of brain damage involving  $A_1$  and  $A_{2A}$  receptors: activation of  $A_1$ Rs would have an important role to control the early onset of brain damage, whereas blockade of  $A_{2A}$ Rs would have a preponderant effect in the latter stages of brain damage. And since the efficiency of  $A_1$ Rs decreases upon chronic noxious stimuli (see “Acute  $A_1$  receptor activation increases the threshold for acute neurodegeneration”), whereas the efficiency of  $A_{2A}$ R antagonists seems to be preserved (probably due to the down-regulation of  $A_1$ Rs and up-regulation of  $A_{2A}$ Rs by noxious stimuli), the use of  $A_{2A}$ R antagonists currently seems to be the most promising brain neuroprotective strategy based on the adenosine neuromodulatory system in adult animals [325]. Accordingly,  $A_{2A}$ R antagonists are being developed as novel anti-parkinsonian drugs [326–328], which are currently under clinical trials with promising results (e.g., [329]).

However, it might still be possible to further refine the efficiency of a neuroprotective strategy based on adenosine neuromodulation. In fact, although there is a general down-regulation of  $A_1$ Rs caused by noxious stimuli, this does not mean that the ability of  $A_1$ Rs to control neuronal damage is eliminated. In fact, some reports indicate that  $A_1$ R-mediated neuroprotective effects may still be achieved in chronic brain noxious conditions in adult animals, such as in animal models of epilepsy [165, 330, 331], multiple sclerosis [332], paroxysmal dystonia [333] or 3-nitropropionic acid-induced neurotoxicity [334]. It has already been discussed that the use of  $A_1$ R agonists as neuroprotective tools *in vivo* may be of limited use because of their profound peripheral effects (see “Acute  $A_1$  receptor activation increases the threshold for acute neurodegeneration”). However, it might be possible to explore the potential of inhibitors of the main enzymatic pathway controlling the consumption of adenosine in the brain, i.e. adenosine kinase. Some concerns were initially raised with respect to the efficiency of this approach, because it was reported that ischemia might cause a down-regulation of this enzymatic activity in cultured cells [122, 335, 368]. However, a recent careful study carried out *in vivo* established the maintenance of the activity of adenosine kinase after convulsions and most importantly, showed that the inhibition of adenosine kinase was effective over long periods of time (up to 1 month in rodents), without

observable peripheral side effects [165]. Thus, it is now proposed that the simultaneous enhancement of the extracellular levels of adenosine by inhibition of adenosine kinase (to burst  $A_1$ R activation) together with antagonists of  $A_{2A}$ Rs might be the most efficient neuroprotective strategy based on adenosine neuromodulation to prevent brain damage in adult animals. It is hoped that this hypothesis might be confirmed in animal models of disease in the future.

### The consequences of adenosine neuroprotection differ in the newborns

Whereas it is now possible to draw a consistent picture about the roles of  $A_1$  and  $A_{2A}$  receptors in controlling neuronal damage in adult animals, the same is not true in the case of fetus or newborns animals. Brain  $A_1$ Rs and  $A_{2A}$ Rs are ontogenically regulated and, although  $A_1$  and  $A_{2A}$  receptors are already present at early developmental timepoints, their expression and density undergo a striking burst at birth and major increases until P9–P15 [336–340]. Some groups [338, 341] suggested that the efficiency of  $A_1$ Rs might be reduced in the immature brain. However, several central  $A_1$ R-mediated effects, like the control of epileptogenesis [342–344], of axonal growth [345, 346], of brain metabolism [347] and of synaptic transmission [348] have been documented to occur in pups or newborn animals, suggesting that  $A_1$ Rs are functional (reviewed in [349]). However,  $A_1$ R agonists seem to be essentially ineffective in protecting against ischemia-induced damage in the immature brain [341, 350]. The activation of  $A_1$ Rs might even be detrimental for the immature brain, since  $A_1$ R activation inhibits neurite outgrowth [351, 352], which may be the reason for the ability of caffeine and  $A_1$ R antagonists to prevent the prevalent condition of periventricular leukomalacia in newborns [346]. Interestingly, the acute increase of extracellular adenosine affords neuroprotection against ischemic insults in the immature brain [353]. This may make sense if one considers that the role of  $A_{2A}$ Rs in controlling neuronal damage is also the opposite in the immature brain and in adult animals. In fact, whereas  $A_{2A}$ R blockade is a consistent neuroprotective strategy against brain damage in adult animals, brain damage is aggravated in immature  $A_{2A}$ R knockout mice [354].

In conclusion, it appears that the roles of adenosine in the control of brain damage are fundamentally the opposite in fetus/newborns and in adult animals. Thus, whereas  $A_1$ R activation affords neuroprotection in the adult animals, its role in the immature brain might be predominantly deleterious [346]. In contrast, whereas blockade of  $A_{2A}$ Rs confers brain neuroprotection in adult animals, it aggravates damage in the immature brain. This opposite impact of adenosine receptor activation on neuronal viability might not necessarily be due to a different functioning of  $A_1$ Rs and  $A_{2A}$ Rs in immature and mature neurons, but instead to an opposite effect of intracellular calcium levels in immature and mature neurons. In fact, whereas the

activation of NMDA receptors and the rise in intracellular free calcium concentrations are two well defined hallmarks of neurotoxicity in neurons from adult animals (e.g., [355]), these features appear to be fundamental for the survival of immature neurons [356]. In fact, A<sub>1</sub>R activation in cultured cortical neurons (from newborn rats) decreases NMDA receptor function and voltage activated calcium channels in a manner analogous to that found in adult rats [356–358] but this lead to a decreased neuronal viability [356] rather than a neuroprotection, as observed in adult brain preparations. Thus, it appears that neuronal adenosine receptors maintain their way of functioning in newborn neurons, but it is the mechanism of neuronal death that is fundamentally the opposite in mature and in immature neurons.

These modifications of the effects mediated by adenosine and eventually of the coupling of adenosine receptors should be kept in mind when considering the use of cultured brain cells as experimental models to study purinergic modulation, since these preparations are obtained from embryos or newborns. Some studies in cultured brain preparations found that A<sub>1</sub>R activation or A<sub>2A</sub>R blockade were neuroprotective [263, 264, 359–361], whereas other found patterns of control of neuronal death by manipulation of A<sub>1</sub>Rs [362–364] or A<sub>2A</sub>Rs [365, 366] different from these observed in adult animals. Furthermore, there is evidence to suggest that the metabolism of adenosine in preparations from newborn animals [348] or in neuronal cell cultures [367, 368] also differs from adenosine metabolism in brain preparations of adult animals.

### Adenosine neuroprotection and neurodegenerative diseases on aging

The word of caution on the possible limitations of the extrapolation of the usefulness of the adenosine system for neuroprotection, from adult animals to the immature brain, obviously raises the question of the applicability of the proposed strategies of adenosine neuroprotection in the elderly. This is particularly relevant since most of the proposed therapeutic applications based on the manipulation of the adenosine system (Parkinson's and Alzheimer's disease, brain ischemic conditions, epilepsy, sleep disorders) are prevalent in the elderly, but the experimental work is largely carried out in young adult animals. Thus, one issue that needs to be established before translation of animal work into disease in humans is whether there are changes in the adenosine neuromodulatory system on aging, as it was found to occur for the immature brain.

In aged animals, it is observed that there is a decreased expression [369] and density of A<sub>1</sub>Rs in cortical and hippocampal regions ([370–375]; but see [376]), whereas the density of A<sub>2A</sub>Rs increases [31, 372, 377]. This is paralleled by a decreased efficiency of A<sub>1</sub>R agonists [375, 378–380] and by an increased G protein coupling [377] and efficiency of A<sub>2A</sub>Rs in limbic regions [31, 377]. Interestingly, the modification of the status of A<sub>2A</sub>Rs in aged animals is different in the basal ganglia from that in cortical regions. In fact, there is a decreased expression

[381] and density of A<sub>2A</sub>R in the striatum of aged rats [376, 382–384]. However, since the role of A<sub>2A</sub>Rs in motor control is tightly linked to dopaminergic signalling (reviewed in [6, 28]) and there is also a reduction in the density of dopamine D<sub>2</sub> receptors in the striatum of aged rats even greater than that of A<sub>2A</sub>Rs [382, 383], the motor effects of A<sub>2A</sub>R antagonists are increased in aged animals [385]. This again stresses the differences between striatal and extra-striatal A<sub>2A</sub>R and the limitations in extrapolating any information from striatal A<sub>2A</sub>Rs to our understanding of the role of extra-striatal A<sub>2A</sub>Rs. It is interesting to note that the changes in aged animals of the relative density of A<sub>1</sub>Rs *versus* A<sub>2A</sub>Rs in cortical regions is similar to that found upon noxious brain conditions (i.e., down-regulation of A<sub>1</sub>Rs and up-regulation of A<sub>2A</sub>Rs). This opens the question of whether the change of status of A<sub>1</sub>/A<sub>2A</sub> receptors in aged animals results from aging viewed as a physiological stress condition or whether the modification of the adenosine receptor system evolves to compensate the general loss of efficiency of functioning of brain circuits [386, 387]. Future aging studies (rather than comparisons between groups of adult and aged animals) will be required to elucidate these issues. This might be particularly relevant in view of the observation that A<sub>1</sub>Rs seem to control the life-span of mice, since the life expectancy of A<sub>1</sub>R knockout mice is significantly lower than that of their wild-type littermates [388].

In aged animals, there is not only a modification in the densities of A<sub>1</sub>Rs and A<sub>2A</sub>Rs in the brain, but there is also a modification of the extracellular metabolism of adenosine (see data and references in [118]). The most surprising observation is that there is a major decrease in the tonic A<sub>1</sub>R activation in hippocampal preparations from aged rats ([380]; in agreement with the results in [375, 379, 389]; but see [390–392]). This might eventually contribute for the greater susceptibility of brain tissue from aged animals to stressful stimuli, since the main role of A<sub>1</sub>Rs appears to be the control of the threshold of onset of neuronal damage.

However, these studies comparing the extracellular metabolism and A<sub>1</sub> *versus* A<sub>2A</sub> receptor-mediated effects between young adult and aged animals allow anticipating that the currently proposed best adenosine-based strategy for neuroprotection seems particularly adequate for aged animals. In fact, in aged animals there is a decrease in the extracellular levels of adenosine acting on A<sub>1</sub>Rs and there are increased levels of A<sub>2A</sub>Rs that are more efficient than in the brain from young adult animals. Thus the combination of adenosine kinase inhibitors with antagonists of A<sub>2A</sub>Rs might be particularly effective in aged animals. It is hoped that future work will allow confirming the neuroprotective efficiency of the combination of these drugs in aged animals. Also, careful parallel studies will be required to test if there are unexpected secondary effects that may appear only in aged animals. In fact, the pharmacokinetics of most drugs is considerably changed in aged animals, and some pharmacodynamic characteristics are also modified, like, for instance, the cardiovascular effects of adenosine in aged rats [393–395].

## Acknowledgements

The experimental work carried out by my group 'Purines at CNC' ([http://cnc.cj.uc.pt/lab\\_lef/](http://cnc.cj.uc.pt/lab_lef/)) was supported by Fundação para a Ciência e para a Tecnologia (grant no. 44740/2002) and by Sociedade Portuguesa de Neurociências. I am indebted to the members of my group for helpful suggestions, and particularly to Lisiane Porciúncula and Nelson Rebola for carefully reviewing the MS and to Attila Kofalvi for his generous help in drawing the pictures of this review. Most of the ideas presented result from discussions with our mentor Bertil Fredholm (Karolinska Institutet, Sweden) and with Jiang-Fan Chen (Harvard University, USA) to whom I am in debt.

## References

- Cunha RA. Adenosine as a neuromodulator and as a homeostatic regulator in the nervous system: Different roles, different sources and different receptors. *Neurochem Int* 2001; 38: 107–25.
- Newby AC. Adenosine and the concept of "retaliatory metabolites." *Trends Biochem* 1984; 9: 42–4.
- Lefkowitz RJ. Historical review: A brief history and personal retrospective of seven transmembrane receptors. *Trends Pharmacol Sci* 2004; 25: 413–22.
- Fredholm BB, Ijzerman AP, Jacobson KA et al. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev* 2001; 53: 527–52.
- Fastbom J, Pazos A, Palacios JM. The distribution of adenosine A<sub>1</sub> receptors and 5'-nucleotidase in the brain of some commonly used experimental animals. *Neuroscience* 1987; 22: 813–26.
- Fredholm BB, Cunha R, Svenningsson P. Pharmacology of adenosine A<sub>2A</sub> receptors and therapeutic applications. *Curr Top Med Chem* 2003; 3: 413–26.
- Lopes LV, Halldner L, Rebola N et al. Binding of the prototypical adenosine A<sub>2A</sub> receptor agonist CGS 21680 to the cerebral cortex of adenosine A<sub>1</sub> and A<sub>2A</sub> receptor knockout mice. *Br J Pharmacol* 2004; 141: 1006–14.
- Halldner L, Lopes LV, Lindström K et al. Binding of adenosine receptor ligands to brain of adenosine receptor knock-out mice – Evidence that CGS 21680 binds to A<sub>1</sub> receptors in hippocampus. *Naunyn-Schmiedeberg's Arch Pharmacol* 2004; 370: 270–8.
- Lupica CR, Cass WA, Zahniser NR, Dunwiddie TV. Effects of the selective adenosine A<sub>2</sub> receptor agonist CGS 21680 on *in vitro* electrophysiology, cAMP formation and dopamine release in rat hippocampus and striatum. *J Pharmacol Exp Ther* 1990; 252: 1134–41.
- Ciruela F, Saura C, Canela EI et al. Ligand induced phosphorylation, clustering, and desensitization of A<sub>1</sub> adenosine receptors. *Mol Pharmacol* 1997; 52: 788–97.
- Canals M, Burgueno J, Marcellino D et al. Homodimerization of adenosine A<sub>2A</sub> receptors: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. *J Neurochem* 2004; 88: 726–34.
- Yoshioka K, Hosoda R, Kuroda Y, Nakata H. Hetero-oligomerization of adenosine A<sub>1</sub> receptors with P2Y<sub>1</sub> receptors in rat brains. *FEBS Lett* 2002; 531: 299–303.
- Ciruela F, Escriche M, Burgueno J et al. Metabotropic glutamate 1alpha and adenosine A<sub>1</sub> receptors assemble into functionally interacting complexes. *J Biol Chem* 2004; 276: 18345–51.
- Canals M, Marcellino D, Fanelli F et al. Adenosine A<sub>2A</sub>-dopamine D<sub>2</sub> receptor-receptor heteromerization: Qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. *J Biol Chem* 2003; 278: 46741–9.
- Ferré S, Karcz-Kubicha M, Hope BT et al. Synergistic interaction between adenosine A<sub>2A</sub> and glutamate mGlu5 receptors: Implications for striatal neuronal function. *Proc Natl Acad Sci USA* 2002; 99: 11940–5.
- Nishi A, Liu F, Matsuyama S et al. Metabotropic mGlu5 receptors regulate adenosine A<sub>2A</sub> receptor signalling. *Proc Natl Acad Sci USA* 2003; 100: 1322–7.
- Biber K, Klotz KN, Berger M et al. Adenosine A<sub>1</sub> receptor-mediated activation of phospholipase C in cultured astrocytes depends on the level of receptor expression. *J Neurosci* 1997; 17: 4956–64.
- Gebicke-Haerter PJ, Christoffel F, Timmer J et al. Both adenosine A<sub>1</sub>- and A<sub>2</sub>-receptors are required to stimulate microglial proliferation. *Neurochem Int* 1996; 29: 37–42.
- Othman T, Yan H, Rivkees SA. Oligodendrocytes express functional A<sub>1</sub> adenosine receptors that stimulate cellular migration. *Glia* 2003; 44: 166–72.
- Swanson TH, Drazba JA, Rivkees SA. Adenosine A<sub>1</sub> receptors are located predominantly on axons in the rat hippocampal formation. *J Comp Neurol* 1995; 363: 517–31.
- Phillips GR, Huang JK, Wang Y et al. The presynaptic particle web: Ultrastructure, composition, dissolution, and reconstitution. *Neuron* 2001; 32: 1–20.
- Tetzlaff W, Schubert P, Kreutzberg GW. Synaptic and extrasynaptic localization of adenosine binding sites in the rat hippocampus. *Neuroscience* 1987; 21: 869–75.
- Rebola N, Pinheiro PC, Oliveira CR et al. Subcellular localization of adenosine A<sub>1</sub> receptors in nerve terminals and synapses of the rat hippocampus. *Brain Res* 2003; 987: 49–58.
- Svenningsson P, Le Moine C, Fisone G, Fredholm BB. Distribution, biochemistry and function of striatal adenosine A<sub>2A</sub> receptors. *Prog Neurobiol* 1999; 59: 355–96.
- Hettinger BD, Lee A, Linden J, Rosin DL. Ultrastructural localization of adenosine A<sub>2A</sub> receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. *J Comp Neurol* 2001; 431: 331–46.
- Rodrigues RJ, Alfaro TM, Rebola N et al. Co-localization and functional interaction between adenosine A<sub>2A</sub> and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. *J Neurochem* 2004; (in press).
- Mori A, Shindou T, Ichimura M et al. The role of adenosine A<sub>2A</sub> receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. *J Neurosci* 1996; 16: 605–11.
- Ferré S, Ciruela F, Woods AS et al. Glutamate mGlu<sub>5</sub>-adenosine A<sub>2A</sub>-dopamine D<sub>2</sub> receptor interactions in the striatum. Implications for drug therapy in neuro-psychiatric disorders and drug abuse. *Curr Med Chem* 2003; 3: 1–26.
- Cunha RA, Johansson B, van der Ploeg I et al. Evidence for functionally important adenosine A<sub>2A</sub> receptors in the rat hippocampus. *Brain Res* 1994; 649: 208–16.
- Rebola N, Oliveira CR, Cunha RA. Transducing system operated by adenosine A<sub>2A</sub> receptors to facilitate acetylcholine release in the rat hippocampus. *Eur J Pharmacol* 2002; 454: 31–8.
- Rebola N, Sebastião AM, de Mendonça A et al. Enhanced adenosine A<sub>2A</sub> receptor facilitation of synaptic transmission in the hippocampus of aged rats. *J Neurophysiol* 2003; 90: 1295–303.
- Lopes LV, Cunha RA, Kull B et al. Adenosine A<sub>2A</sub> receptor facilitation of hippocampal synaptic transmission is dependent on the tonic A<sub>1</sub> receptor inhibition. *Neuroscience* 2002; 112: 319–29.
- Rebola N, Canas P, Oliveira CR, Cunha GMA. Different synaptic and subsynaptic localization of adenosine A<sub>2A</sub> receptors in the hippocampus and striatum of the rat. *Neuroscience* 2005; in press.
- Cunha RA, Milusheva E, Vizi ES et al. Excitatory and inhibitory effects of A<sub>1</sub> and A<sub>2A</sub> adenosine receptor activation on the electrically evoked [<sup>3</sup>H]acetylcholine release from different areas of the rat hippocampus. *J Neurochem* 1994; 63: 207–14.
- Jin S, Fredholm BB. Adenosine A<sub>2A</sub> receptor stimulation increases release of acetylcholine from rat hippocampus but not striatum, and does not affect catecholamine release. *Naunyn-Schmiedeberg's Arch Pharmacol* 1997; 355: 48–56.
- Okada M, Nutt DJ, Murakami T et al. Adenosine receptor subtypes modulate two major functional pathways for hippocampal serotonin release. *J Neurosci* 2001; 21: 628–40.

37. Cunha RA, Ribeiro JA. Purinergic modulation of [<sup>3</sup>H]GABA release from rat hippocampal nerve terminals. *Neuropharmacology* 2000; 39: 1156–67.
38. Barraco RA, Helfman CC, Goodwin BP, Anderson GF. Evidence for presynaptic adenosine A<sub>2A</sub> receptors associated with norepinephrine release and their desensitisation in the rat nucleus tractus solitarius. *J Neurochem* 1995; 65: 1604–11.
39. Li XX, Nomura T, Aihara H, Nishizaki T. Adenosine enhances glial glutamate efflux via A<sub>2A</sub> adenosine receptors. *Life Sci* 2001; 68: 1343–50.
40. Nishizaki T, Nagai K, Nomura T et al. A new neuromodulatory pathway with a glial contribution mediated via A<sub>2A</sub> adenosine receptors. *Glia* 2002; 39: 133–47.
41. Küst BM, Biber K, van Calker D, Gebicke-Haerter PJ. Regulation of K<sup>+</sup> channel mRNA expression by stimulation of adenosine A<sub>2a</sub>-receptors in cultured rat microglia. *Glia* 1999; 25: 120–30.
42. Fiebich BL, Biber K, Lieb K et al. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A<sub>2a</sub>-receptors. *Glia* 1996; 18: 152–60.
43. Coney AM, Marshall JM. Role of adenosine and its receptors in the vasodilatation induced in the cerebral cortex of the rat by systemic hypoxia. *J Physiol* 1998; 509: 507–18.
44. Ngai AC, Coyne EF, Meno JR et al. Receptor subtypes mediating adenosine-induced dilation of cerebral arterioles. *Am J Physiol* 2001; 280: H2329–35.
45. Díaz-Hernández M, Pereira MF, Pintor J et al. Modulation of the rat hippocampal dinucleotide receptor by adenosine receptor activation. *J Pharmacol Exp Ther* 2002; 301: 441–50.
46. Lopes LV, Rebola N, Pinheiro PC et al. Adenosine A<sub>3</sub> receptors are located in neurons of the rat hippocampus. *NeuroReport* 2003; 14: 1645–8.
47. Brand A, Vissienon Z, Eschke D, Nieber K. Adenosine A<sub>1</sub> and A<sub>3</sub> receptors mediate inhibition of synaptic transmission in rat cortical neurons. *Neuropharmacology* 2001; 40: 85–95.
48. Costenla AR, Lopes LV, de Mendonça A, Ribeiro JA. A functional role for adenosine A<sub>3</sub> receptors: Modulation of synaptic plasticity in the rat hippocampus. *Neurosci Lett* 2001; 302: 53–7.
49. Abbracchio MP, Ceruti S, Brambilla R et al. Adenosine A<sub>3</sub> receptors and viability in astrocytes. *Drug Dev Res* 1998; 45: 379–86.
50. Hammarberg C, Schulte G, Fredholm BB. Evidence for functional adenosine A<sub>3</sub> receptors in microglia cells. *J Neurochem* 2003; 86: 1051–4.
51. Allaman I, Lengacher S, Magistretti PJ, Pellerin L. A<sub>2B</sub> receptor activation promotes glycogen synthesis in astrocytes through modulation of gene expression. *Am J Physiol* 2003; 284: C696–704.
52. Mogul DJ, Adams ME, Fox AP. Differential activation of adenosine receptors decreases N-type but potentiates P-type Ca<sup>2+</sup> current in hippocampal CA3 neurons. *Neuron* 1993; 10: 327–34.
53. Phillis JW, Wu PH. The role of adenosine and its nucleotides in central synaptic transmission. *Prog Neurobiol* 1981; 16: 187–239.
54. Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. *Annu Rev Neurosci* 2001; 24: 31–55.
55. Greene RW, Haas HL. The electrophysiology of adenosine in the mammalian central nervous system. *Prog Neurobiol* 1991; 36: 329–41.
56. Johansson B, Halldner L, Dunwiddie TV et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A<sub>1</sub> receptor. *Proc Natl Acad Sci USA* 2001; 98: 9407–12.
57. Proctor WR, Dunwiddie TV. Pre- and postsynaptic actions of adenosine in the *in vitro* rat hippocampus. *Brain Res* 1987; 426: 187–90.
58. Thompson SM, Haas HL, Gähwiler BH. Comparison of the actions of adenosine at pre- and postsynaptic receptors in the rat hippocampus *in vitro*. *J Physiol* 1992; 451: 347–63.
59. Moore KA, Nicoll RA, Schmitz D. Adenosine gates synaptic plasticity at hippocampal mossy fiber synapses. *Proc Natl Acad Sci USA* 2003; 24: 14397–402.
60. Khan GM, Smolders I, Ebinger G, Michotte Y. 2-Chloro-N<sup>6</sup>-cyclopentyladenosine-elicited attenuation of evoked glutamate release is not sufficient to give complete protection against pilocarpine-induced seizures in rats. *Neuropharmacology* 2001; 40: 657–67.
61. de Mendonça A, Ribeiro JA. Adenosine and neuronal plasticity. *Life Sci* 1997; 60: 245–51.
62. de Mendonça A, Sebastião AM, Ribeiro JA. Inhibition of NMDA receptor-mediated currents in isolated rat hippocampal neurones by adenosine A<sub>1</sub> receptor activation. *NeuroReport* 1995; 6: 1097–100.
63. Klishin A, Lozovaya N, Krishtal O. A<sub>1</sub> adenosine receptors differentially regulate the N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated components of hippocampal excitatory postsynaptic current in a Ca<sup>2+</sup>/Mg<sup>2+</sup>-dependent manner. *Neuroscience* 1995; 65: 947–53.
64. Li H, Henry JL. Adenosine A<sub>2</sub> receptor mediation of pre- and postsynaptic excitatory effects of adenosine in rat hippocampus *in vitro*. *Eur J Pharmacol* 1998; 347: 173–82.
65. Rebola N, Rodrigues RJ, Lopes LV et al. Adenosine A<sub>1</sub> and A<sub>2A</sub> receptors are co-expressed in pyramidal neurons and co-localized in glutamatergic nerve terminals of the rat hippocampus. *Neuroscience* 2005; in press.
66. Lopes LV, Cunha RA, Ribeiro JA. Crosstalk between A<sub>1</sub> and A<sub>2A</sub> adenosine receptors in the hippocampus and cortex of young adult and old rats. *J Neurophysiol* 1999; 82: 3196–203.
67. Sebastião AM, Ribeiro JA. Fine-tuning neuromodulation by adenosine. *Trends Pharmacol Sci* 2000; 21: 341–6.
68. Correia-de-Sá P, Ribeiro JA. Tonic adenosine A<sub>2A</sub> receptor activation modulates nicotinic autoreceptor function at the rat neuromuscular junction. *Eur J Pharmacol* 1994; 271: 349–55.
69. Oliveira L, Timóteo MA, Correia-de-Sá P. Modulation by adenosine of both muscarinic M1-facilitation and M2-inhibition of [<sup>3</sup>H]-acetylcholine release from the rat motor nerve terminals. *Eur J Neurosci* 2002; 15: 1728–36.
70. Correia-de-Sá P, Ribeiro JA. Potentiation by tonic A<sub>2a</sub>-adenosine receptor activation of CGRP-facilitated [<sup>3</sup>H]-ACh release from rat motor nerve endings. *Br J Pharmacol* 1994; 111: 582–8.
71. Correia-de-Sá P, Timóteo MA, Ribeiro JA. Synergism between A<sub>2A</sub>-adenosine receptor activation and vasoactive intestinal peptide to facilitate [<sup>3</sup>H]-acetylcholine release from the rat motor nerve terminals. *Neurosci Lett* 2001; 309: 101–4.
72. Sebastião AM, Macedo MP, Ribeiro JA. Tonic activation of A<sub>2A</sub> adenosine receptors unmasks, and of A<sub>1</sub> receptors prevents, a facilitatory action of calcitonin gene-related peptide in the rat hippocampus. *Br J Pharmacol* 2000; 129: 374–80.
73. Cunha-Reis D, Sebastião AM, Ribeiro JA. Adenosine modulation and transduction mechanisms involved in the action of VIP on [<sup>3</sup>H]-GABA release from hippocampal synaptosomes. *Drug Dev Res* 2000; 50: 83.
74. Diógenes MJ, Fernandes CC, Sebastião AM, Ribeiro JA. Activation of adenosine A<sub>2A</sub> receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. *J Neurosci* 2004; 24: 2905–13.
75. Lee FS, Chao MV. Activation of Trk neurotrophin receptors in the absence of neurotrophins. *Proc Natl Acad Sci USA* 2001; 98: 3555–60.
76. Queiróz G, Talaia C, Goncalves J. Adenosine A<sub>2A</sub> receptor-mediated facilitation of noradrenaline release involves protein kinase C activation and attenuation of presynaptic inhibitory receptor-mediated effects in the rat vas deferens. *J Neurochem* 2003; 85: 740–8.
77. Hosli E, Hosli L. Autoradiographic studies on the uptake of adenosine and on binding of adenosine analogues in neurons and astrocytes of cultured rat cerebellum and spinal cord. *Neuroscience* 1988; 24: 621–8.
78. Peakman MC, Hill SJ. Adenosine A<sub>2B</sub>-receptor-mediated cyclic AMP accumulation in primary rat astrocytes. *Br J Pharmacol* 1994; 111: 191–8.
79. Ogata T, Nakamura Y, Schubert P. Potentiated cAMP rise in metabotropically stimulated rat cultured astrocytes by a Ca<sup>2+</sup>-related



- A<sub>1</sub>/A<sub>2</sub> adenosine receptor cooperation. *Eur J Neurosci* 1996; 8: 1124–31.
80. Pilitsis JG, Kimelberg HK. Adenosine receptor mediated stimulation of intracellular calcium in acutely isolated astrocytes. *Brain Res* 1998; 798: 294–303.
  81. Biber K, Fiebich BL, Gebicke-Harter P, van Calker D. Carbamazepine-induced upregulation of adenosine A<sub>1</sub>-receptors in astrocyte cultures affects coupling to the phosphoinositol signaling pathway. *Neuropsychopharmacology* 1999; 20: 271–8.
  82. Ciccarelli R, Ballerini P, Sabatino G et al. Involvement of astrocytes in purine-mediated reparative processes in the brain. *Int J Dev Neurosci* 2001; 19: 395–414.
  83. Hindley S, Herman MA, Rathbone MP. Stimulation of reactive astrogliosis *in vivo* by extracellular adenosine diphosphate or an adenosine A<sub>2</sub> receptor agonist. *J Neurosci Res* 1994; 38: 399–406.
  84. Brambilla R, Cottini L, Fumagalli M et al. Blockade of A<sub>2A</sub> adenosine receptors prevents basic fibroblast growth factor-induced reactive astrogliosis in rat striatal primary astrocytes. *Glia* 2003; 43: 190–4.
  85. Schwaninger M, Neher M, Viegas E et al. Stimulation of interleukin-6 secretion and gene transcription in primary astrocytes by adenosine. *J Neurochem* 1997; 69: 1145–50.
  86. Brodie C, Blumberg PM, Jacobson KA. Activation of the A<sub>2A</sub> adenosine receptor inhibits nitric oxide production in glial cells. *FEBS Lett* 1998; 429: 139–42.
  87. Ciccarelli R, Di Iorio P, Bruno V et al. Activation of A<sub>1</sub> adenosine or mGlu3 metabotropic glutamate receptors enhances the release of nerve growth factor and S-100beta protein from cultured astrocytes. *Glia* 1999; 27: 275–81.
  88. Wittendorp MC, Boddeke HW, Biber K. Adenosine A<sub>3</sub> receptor-induced CCL2 synthesis in cultured mouse astrocytes. *Glia* 2004; 46: 410–8.
  89. Toms NJ, Roberts PJ. Group 1 mGlu receptors elevate [Ca<sup>2+</sup>]<sub>i</sub> in rat cultured cortical type 2 astrocytes: [Ca<sup>2+</sup>]<sub>i</sub> synergy with adenosine A<sub>1</sub> receptors. *Neuropharmacology* 1999; 38: 1511–7.
  90. Cormier RJ, Mennerick S, Melbostad H, Zorumski CF. Basal levels of adenosine modulate mGluR5 on rat hippocampal astrocytes. *Glia* 2001; 33: 24–35.
  91. Peakman MC, Hill SJ. Adenosine A<sub>1</sub> receptor-mediated changes in basal and histamine-stimulated levels of intracellular calcium in primary rat astrocytes. *Br J Pharmacol* 1995; 115: 801–10.
  92. el-Etr M, Lombs M, Baulieu EE, Erlanger BF. A monoclonal anti-idiotypic 'internal image' antibody that recognizes the A<sub>1</sub> adenosine receptor potentiates the alpha 1-adrenergic activation of phospholipase C in primary cultures of mouse striatal astrocytes. *Neurosci Lett* 1992; 145: 15–8.
  93. Jimenez AI, Castro E, Mirabet M et al. Potentiation of ATP calcium responses by A<sub>2B</sub> receptor stimulation and other signals coupled to Gs proteins in type-1 cerebellar astrocytes. *Glia* 1999; 26: 119–28.
  94. Alloisio S, Cugnoli C, Ferroni S, Nobile M. Differential modulation of ATP-induced calcium signalling by A<sub>1</sub> and A<sub>2</sub> adenosine receptors in cultured cortical astrocytes. *Br J Pharmacol* 2004; 141: 935–42.
  95. Schwaninger M, Petersen N, Prinz S et al. Adenosine-induced expression of interleukin-6 in astrocytes through protein kinase A and NF-IL-6. *Glia* 2000; 31: 51–8.
  96. Fiebich BL, Biber K, Gyufko K et al. Adenosine A<sub>2b</sub> receptors mediate an increase in interleukin (IL)-6 mRNA and IL-6 protein synthesis in human astroglia cells. *J Neurochem* 1996; 66: 1426–31.
  97. Si QS, Nakamura Y, Schubert P et al. Adenosine and propentofylline inhibit the proliferation of cultured microglial cells. *Exp Neurol* 1996; 137: 345–9.
  98. Flavin MP, Ho LT. Propentofylline protects neurons in culture from death triggered by macrophage or microglial secretory products. *J Neurosci Res* 1999; 56: 54–9.
  99. Wollmer MA, Lucius R, Wilms H et al. ATP and adenosine induce ramification of microglia *in vitro*. *J Neuroimmunol* 2001; 115: 19–27.
  100. Schubert P, Ogata T, Ferroni S et al. Modulation of glial cell signaling by adenosine and pharmacological reinforcement. A neuroprotective strategy? *Mol Chem Neurobiol* 1996; 28: 185–90.
  101. Haberg A, Qu H, Haraldseth O et al. *In vivo* effects of adenosine A<sub>1</sub> receptor agonist and antagonist on neuronal and astrocytic intermediary metabolism studied with *ex vivo* <sup>13</sup>C NMR spectroscopy. *J Neurochem* 2000; 74: 327–33.
  102. Hammer J, Qu H, Haberg A, Sonnewald U. *In vivo* effects of adenosine A<sub>2</sub> receptor agonist and antagonist on neuronal and astrocytic intermediary metabolism studied with *ex vivo* <sup>13</sup>C MR spectroscopy. *J Neurochem* 2001; 79: 885–92.
  103. Magistretti PJ, Hof PR, Martin JL. Adenosine stimulates glycogenolysis in mouse cerebral cortex: A possible coupling mechanism between neuronal activity and energy metabolism. *J Neurosci* 1986; 6: 2558–62.
  104. Sorg O, Magistretti PJ. Characterization of the glycogenolysis elicited by vasoactive intestinal peptide, noradrenaline and adenosine in primary cultures of mouse cerebral cortical astrocytes. *Brain Res* 1991; 563: 227–33.
  105. Rathbone MP, Middlemiss PJ, Gysbers JW et al. Trophic effects of purines in neurons and glial cells. *Prog Neurobiol* 1999; 59: 663–90.
  106. Geiger JD, Fyda DM. Adenosine transport in nervous system tissues. In Stone TW (ed): *Adenosine in the Nervous System*. London: Academic Press 1991; 1–23.
  107. MacDonald WF, White TD. Nature of extrasynaptosomal accumulation of endogenous adenosine evoked by K<sup>+</sup> and veratridine. *J Neurochem* 1985; 45: 791–7.
  108. Cunha RA, Almeida T, Ribeiro JA. Modification by arachidonic acid of extracellular adenosine metabolism and neuromodulatory action in the rat hippocampus. *J Biol Chem* 2000; 275: 37572–81.
  109. Cunha RA. Regulation of the ecto-nucleotidase pathway in rat hippocampal nerve terminals. *Neurochem Res* 2001; 26: 979–91.
  110. Zimmermann H. Signalling via ATP in the nervous system. *Trends Neurosci* 1994; 17: 420–6.
  111. Wieraszko A, Goldsmith G, Seyfried TN. Stimulation-dependent release of adenosine triphosphate from hippocampal slices. *Brain Res* 1989; 485: 244–50.
  112. Cunha RA, Vizi ES, Ribeiro JA, Sebastião AM. Preferential release of ATP and its extracellular catabolism as a source of adenosine upon high- but not low-frequency stimulation of rat hippocampal slices. *J Neurochem* 1996; 67: 2180–7.
  113. Correia-de-Sá P, Timóteo MA, Ribeiro JA. Presynaptic A<sub>1</sub> inhibitory/A<sub>2A</sub> facilitatory adenosine receptor activation balance depends on motor nerve stimulation paradigm at the rat hemidiaphragm. *J Neurophysiol* 1996; 76: 3910–9.
  114. Correia-de-Sá P, Ribeiro JA. Adenosine uptake and deamination regulate tonic A<sub>2a</sub> receptor facilitation of evoked [<sup>3</sup>H]acetylcholine release from the rat motor nerve terminals. *Neuroscience* 1996; 73: 85–92.
  115. Cunha RA, Constantino MD, Ribeiro JA. ZM241385 is an antagonist of the facilitatory responses produced by the A<sub>2A</sub> adenosine receptor agonists CGS21680 and HENECA in the rat hippocampus. *Br J Pharmacol* 1997; 122: 1279–84.
  116. Costenla AR, Coelho JE, de Mendonça A et al. Endogenous adenosine A<sub>2A</sub> receptor activation tonically enhances the magnitude of LTP in the rat hippocampus. 4th Forum of European Neuroscience 2004; A015.14.
  117. Cunha RA, Correia-de-Sá P, Sebastião AM, Ribeiro JA. Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. *Br J Pharmacol* 1996; 119: 253–60.
  118. Cunha RA, Almeida T, Ribeiro JA. Parallel modification of adenosine extracellular metabolism and modulatory action in the hippocampus of aged rats. *J Neurochem* 2001; 76: 372–82.
  119. Agostinho P, Caseiro P, Rego AC et al. Adenosine modulation of D-[<sup>3</sup>H]aspartate release in cultured retina cells exposed to oxidative stress. *Neurochem Int* 2000; 36: 255–65.
  120. Rebola N, Coelho JE, Costenla AR et al. Decrease of adenosine A<sub>1</sub> receptor density and of adenosine neuromodulation in the hippocampus of kindled rats. *Eur J Neurosci* 2003; 18: 820–8.

121. Kobayashi S, Millhorn DE. Stimulation of expression for the adenosine A<sub>2A</sub> receptor gene by hypoxia in PC12 cells. A potential role in cell protection. *J Biol Chem* 1999; 274: 20358–65.
122. Kobayashi S, Zimmermann H, Millhorn DE. Chronic hypoxia enhances adenosine release in rat PC12 cells by altering adenosine metabolism and membrane transport. *J Neurochem* 2000; 74: 621–32.
123. Napieralski R, Kempkes B, Gutensohn W. Evidence for coordinated induction and repression of ecto-5'-nucleotidase (CD73) and the A<sub>2a</sub> adenosine receptor in a human B cell line. *Biol Chem* 2003; 384: 483–7.
124. Latini S, Pedata F. Adenosine in the central nervous system: Release mechanisms and extracellular concentrations. *J Neurochem* 2001; 79: 463–84.
125. Bodin P, Burnstock G. Purinergic signalling: ATP release. *Neurochem Res* 2001; 268: 959–69.
126. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. *Naunyn-Schmiedeberg's Arch Pharmacol* 2000; 362: 299–309.
127. Cunha RA, Sebastião AM, Ribeiro JA. Inhibition by ATP of hippocampal synaptic transmission requires localized extracellular catabolism by ecto-nucleotidases into adenosine and channeling to adenosine A<sub>1</sub> receptors. *J Neurosci* 1998; 18: 1987–95.
128. Dunwiddie TV, Diao L, Proctor WR. Adenine nucleotides undergo rapid, quantitative conversion to adenosine in the extracellular space in rat hippocampus. *J Neurosci* 1997; 17: 7673–82.
129. Rusakov DA, Harrison E, Stewart MG. Synapses in the hippocampus occupy only 1–2% of cell membranes and are spaced less than half-micron apart: A quantitative ultrastructural analysis with discussion of physiological implications. *Neuropharmacology* 1998; 37: 513–21.
130. Cunha RA, Brendel P, Zimmermann H, Ribeiro JA. Immunologically distinct isoforms of ecto-5'-nucleotidase in nerve terminals of different areas of the rat hippocampus. *J Neurochem* 2000; 74: 334–8.
131. Wang Z, Haydon PG, Yeung ES. Direct observation of calcium-independent intercellular ATP signaling in astrocytes. *Anal Chem* 2000; 72: 2001–7.
132. Arcuino G, Lin JH, Takano T et al. Intercellular calcium signaling mediated by point-source burst release of ATP. *Proc Natl Acad Sci USA* 2002; 99: 9840–5.
133. Coco S, Calegari F, Pravettoni E et al. Storage and release of ATP from astrocytes in culture. *J Biol Chem* 2003; 278: 1354–62.
134. Stout CE, Costantin JL, Naus CC, Charles AC. Intercellular calcium signaling in astrocytes via ATP release through connexin hemichannels. *J Biol Chem* 2002; 277: 10482–8.
135. Ballerini P, Di Iorio P, Ciccarelli R et al. Glial cells express multiple ATP binding cassette proteins which are involved in ATP release. *NeuroReport* 2002; 13: 1789–92.
136. Bal-Price A, Moneer Z, Brown GC. Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes. *Glia* 2002; 40: 312–23.
137. Anderson CM, Bergher JP, Swanson RA. ATP-induced ATP release from astrocytes. *J Neurochem* 2004; 88: 246–56.
138. Parkinson FE, Xiong W. Stimulus- and cell-type-specific release of purines in cultured rat forebrain astrocytes and neurons. *J Neurochem* 2004; 88: 1305–12.
139. Koizumi S, Fujishita K, Tsuda M et al. Dynamic inhibition of excitatory synaptic transmission by astrocyte-derived ATP in hippocampal cultures. *Proc Natl Acad Sci USA* 2003; 100: 11023–8.
140. Newman EA. Glial cell inhibition of neurons by release of ATP. *J Neurosci* 2003; 23: 1659–66.
141. Zhang JM, Wang HK, Ye CQ et al. ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression. *Neuron* 2003; 40: 971–82.
142. Seo DR, Kim KY, Lee YB. Interleukin-10 expression in lipopolysaccharide-activated microglia is mediated by extracellular ATP in an autocrine fashion. *NeuroReport* 2004; 15: 1157–61.
143. Rosenberg PA, Li Y. Adenylyl cyclase activation underlies intracellular cyclic AMP accumulation, cyclic AMP transport, and extracellular adenosine accumulation evoked by beta-adrenergic receptor stimulation in mixed cultures of neurons and astrocytes derived from rat cerebral cortex. *Brain Res* 1995; 692: 227–32.
144. Brundage JM, Diao L, Proctor WR, Dunwiddie TV. The role of cyclic AMP as a precursor of extracellular adenosine in the rat hippocampus. *Neuropharmacology* 1997; 36: 1201–10.
145. Fowler JC. Changes in extracellular adenosine levels and population spike amplitude during graded hypoxia in the rat hippocampal slice. *Naunyn-Schmiedeberg's Arch Pharmacol* 1993; 347: 73–8.
146. Doolette DJ. Mechanism of adenosine accumulation in the hippocampal slice during energy deprivation. *Neurochem Int* 1997; 30: 211–23.
147. Phillis JW, O'Regan MH, Walter GA. Effects of deoxycoformycin on adenosine, inosine, hypoxanthine, xanthine, and uric acid release from the hypoxic rat cerebral cortex. *J Cereb Blood Flow Metab* 1988; 8: 733–41.
148. Kobayashi T, Yamada T, Okada Y. The levels of adenosine and its metabolites in the guinea pig and rat brain during complete ischemia – *in vivo* study. *Brain Res* 1998; 787: 211–9.
149. Wieraszko A, Seyfried TN. Increased amount of extracellular ATP in stimulated hippocampal slices of seizure prone mice. *Neurosci Lett* 1989; 106: 287–93.
150. Lutz PL, Kabler S. Release of adenosine and ATP in the brain of the freshwater turtle (*Trachemys scripta*) during long-term anoxia. *Brain Res* 1997; 769: 281–6.
151. Juranyi Z, Sperlagh B, Vizi ES. Involvement of P2 purinoceptors and the nitric oxide pathway in [<sup>3</sup>H]purine outflow evoked by short-term hypoxia and hypoglycemia in rat hippocampal slices. *Brain Res* 1999; 823: 183–90.
152. Parkinson FE, Sinclair CJ, Othman T et al. Differences between rat primary cortical neurons and astrocytes in purine release evoked by ischemic conditions. *Neuropharmacology* 2002; 43: 836–46.
153. Volonté C, Amadio S, Cavaliere F et al. Extracellular ATP and neurodegeneration. *Curr Drug Targets CNS Neurol Disord* 2003; 2: 403–12.
154. Liu GJ, Bennett MR. ATP secretion from nerve trunks and Schwann cells mediated by glutamate. *NeuroReport* 2003; 14: 2079–83.
155. Brown P, Dale N. Spike-independent release of ATP from Xenopus spinal neurons evoked by activation of glutamate receptors. *J Physiol* 2002; 540: 851–60.
156. Vizi ES, Sperlagh B. Receptor- and carrier-mediated release of ATP of postsynaptic origin: Cascade transmission. *Prog Brain Res* 1999; 120: 159–69.
157. Braun N, Zhu Y, Kriegstein J et al. Upregulation of the enzyme chain hydrolyzing extracellular ATP after transient forebrain ischemia in the rat. *J Neurosci* 1998; 18: 4891–900.
158. Bonan CD, Walz R, Pereira GS et al. Changes in synaptosomal ectonucleotidase activities in two rat models of temporal lobe epilepsy. *Epilepsy Res* 2000; 39: 229–38.
159. Fontella FU, Bruno AN, Crema LM et al. Acute and chronic stress alter ecto-nucleotidase activities in synaptosomes from the rat hippocampus. *Pharmacol Biochem Behav* 2004; 78: 341–7.
160. Zhang G, Franklin PH, Murray TF. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. *J Pharmacol Exp Ther* 1993; 264: 1415–24.
161. Miller LP, Jelovich LA, Yao L et al. Pre- and peristroke treatment with the adenosine kinase inhibitor, 5'-deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. *Neurosci Lett* 1996; 220: 73–6.
162. Jiang N, Kowaluk EA, Lee CH et al. Adenosine kinase inhibition protects brain against transient focal ischemia in rats. *Eur J Pharmacol* 1997; 320: 131–7.
163. Tatlisumak T, Takano K, Carano RA et al. Delayed treatment with an adenosine kinase inhibitor, GP683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. *Stroke* 1998; 29: 1952–8.
164. Wiesner JB, Ugarkar BG, Castellino AJ et al. Adenosine kinase inhibitors as a novel approach to anticonvulsant therapy. *J Pharmacol Exp Ther* 1999; 289: 1669–77.

165. Gouder N, Scheurer L, Fritschy JM, Boison D. Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. *J Neurosci* 2004; 24: 692–701.
166. McGaraughty S, Cowart M, Jarvis MF. Recent developments in the discovery of novel adenosine kinase inhibitors: Mechanism of action and therapeutic potential. *CNS Drug Rev* 2001; 7: 415–32.
167. Delaney SM, Sutherland GR, Peeling J, Geiger JD. Failure of 2'-deoxycoformycin to protect against transient forebrain ischemia in rat. *Neurosci Lett* 1993; 149: 31–4.
168. Zhu PJ, Krnjevic K. Endogenous adenosine deaminase does not modulate synaptic transmission in rat hippocampal slices under normoxic or hypoxic conditions. *Neuroscience* 1994; 63: 489–97.
169. Phillis JW, O'Regan MH. Deoxycoformycin antagonizes ischemia-induced neuronal degeneration. *Brain Res Bull* 1989; 22: 537–40.
170. Barankiewicz J, Danks AM, Abushanab E et al. Regulation of adenosine concentration and cytoprotective effects of novel reversible adenosine deaminase inhibitors. *J Pharmacol Exp Ther* 1997; 283: 1230–8.
171. de Mendonça A, Sebastião AM, Ribeiro JA. Adenosine: Does it have a neuroprotective role after all? *Brain Res Brain Res Rev* 2000; 33: 258–74.
172. Fredholm BB. Adenosine and neuroprotection. *Int Rev Neurobiol* 1997; 40: 259–80.
173. Sweeney MI. Neuroprotective effects of adenosine in cerebral ischemia: Window of opportunity. *Neurosci Biobehav Rev* 1997; 21: 207–17.
174. von Lubitz DK. Adenosine and cerebral ischemia: Therapeutic future or death of a brave concept? *Eur J Pharmacol* 1999; 371: 85–102.
175. Rudolphi KA, Schubert P, Parkinson FE, Fredholm BB. Adenosine and brain ischemia. *Cerebrovasc Brain Metab Rev* 1992; 4: 346–69.
176. Phillis JW, Goshgarian HG. Adenosine and neurotrauma: Therapeutic perspectives. *Neurol Res* 2001; 23: 183–9.
177. Halle JN, Kasper CE, Gidday JM, Koos BJ. Enhancing adenosine A<sub>1</sub> receptor binding reduces hypoxic-ischemic brain injury in newborn rats. *Brain Res* 1997; 759: 309–12.
178. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: Biochemistry, physiology, and pharmacology. *Am J Cardiol* 1997; 79: 2–10.
179. Olsson RA, Pearson JD. Cardiovascular purinoceptors. *Physiol Rev* 1990; 70: 761–989.
180. Brodie MS, Lee KS, Fredholm BB et al. Central versus peripheral mediation of responses to adenosine receptor agonists: Evidence against a central mode of action. *Brain Res* 1987; 415: 323–33.
181. Schaddelee MP, Groenendaal D, De Jongh J et al. Population pharmacokinetic modelling of blood-brain barrier transport of synthetic adenosine A<sub>1</sub> receptor agonists. *J Pharmacol Exp Ther* 2004; in press.
182. Bischofberger N, Jacobson KA, von Lubitz DK. Adenosine A<sub>1</sub> receptor agonists as clinically viable agents for treatment of ischemic brain disorders. *Ann NY Acad Sci* 1997; 825: 23–9.
183. Jacobson KA, von Lubitz DK, Daly JW, Fredholm BB. Adenosine receptor ligands: Differences with acute versus chronic treatment. *Trends Pharmacol Sci* 1996; 17: 108–13.
184. Hettinger BD, Leid M, Murray TF. Cyclopentyladenosine-induced homologous down-regulation of A<sub>1</sub> adenosine receptors (A<sub>1</sub>AR) in intact neurons is accompanied by receptor sequestration but not a reduction in A<sub>1</sub>AR mRNA or G-protein alpha-subunit content. *J Neurochem* 1998; 71: 221–30.
185. Wetherington JP, Lambert NA. Differential desensitization of responses mediated by presynaptic and postsynaptic A<sub>1</sub> adenosine receptors. *J Neurosci* 2002; 22: 1248–55.
186. Abbraccio MP, Fogliatto G, Paoletti AM et al. Prolonged *in vitro* exposure of rat brain slices to adenosine analogues: Selective desensitization of A<sub>1</sub> but not A<sub>2</sub> receptors. *Eur J Pharmacol* 1992; 227: 317–24.
187. Vendite D, Sanz JM, Lopez-Alanon DM et al. Desensitization of adenosine A<sub>1</sub> receptor-mediated inhibition of adenylyl cyclase in cerebellar granule cells. *Neurochem Res* 1998; 23: 211–8.
188. Fernandez M, Svenningsson P, Fredholm BB. Adaptive changes in adenosine receptors following long-term treatment with the adenosine receptor agonist R-phenylisopropyl adenosine. *Life Sci* 1996; 58: 769–76.
189. Ruiz A, Sanz JM, González-Calero G et al. Desensitization and internalization of adenosine A<sub>1</sub> receptors in rat brain by *in vivo* treatment with R-PIA: Involvement of coated vesicles. *Biochem Biophys Acta* 1996; 1310: 168–74.
190. Lewin E, Bleck V. Electroshock seizures in mice: Effect on brain adenosine and its metabolites. *Epilepsia* 1981; 22: 577–81.
191. During MJ, Spencer DD. Adenosine: A potential mediator of seizure arrest and postictal refractoriness. *Ann Neurol* 1992; 32: 618–24.
192. Berman RF, Fredholm BB, Aden U, O'Connor WT. Evidence for increased dorsal hippocampal adenosine release and metabolism during pharmacologically induced seizures in rats. *Brain Res* 2000; 872: 44–53.
193. Ochiishi T, Takita M, Ikemoto M et al. Immunohistochemical analysis on the role of adenosine A<sub>1</sub> receptors in epilepsy. *NeuroReport* 1999; 10: 3535–41.
194. Ekonomou A, Sperk G, Kostopoulos G, Angelatou F. Reduction of A<sub>1</sub> adenosine receptors in rat hippocampus after kainic acid-induced limbic seizures. *Neurosci Lett* 2000; 284: 49–52.
195. Rebola N, Porciúncula LO, Oliveira CR et al. Long-term effect of convulsive behaviour on the density of adenosine A<sub>1</sub> and A<sub>2A</sub> receptors in the rat cerebral cortex. *Epilepsia* 2005; in press.
196. Deckert J, Abel F, Kunig G et al. Loss of human hippocampal adenosine A<sub>1</sub> receptors in dementia: Evidence for lack of specificity. *Neurosci Lett* 1998; 244: 1–4.
197. Angelatou F, Pagonopoulou O, Maraziotis T et al. Upregulation of A<sub>1</sub> adenosine receptors in human temporal lobe epilepsy: A quantitative autoradiographic study. *Neurosci Lett* 1993; 163: 11–4.
198. Young D, Dragunow M. Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms. *Neuroscience* 1994; 58: 245–61.
199. Adami M, Bertolli R, Ferri N et al. Effects of repeated administration of selective adenosine A<sub>1</sub> and A<sub>2A</sub> receptor agonists on pentylenetetrazole-induced convulsions in the rat. *Eur J Pharmacol* 1995; 294: 383–9.
200. Onodera H, Sato G, Kogure K. Quantitative autoradiographic analysis of muscarinic cholinergic and adenosine A<sub>1</sub> binding sites after transient forebrain ischemia in the gerbil. *Brain Res* 1987; 415: 309–22.
201. Lee KS, Tetzlaff W, Kreutzberg GW. Rapid down regulation of hippocampal adenosine receptors following brief anoxia. *Brain Res* 1986; 380: 155–8.
202. Nagasawa H, Araki T, Kogure K. Alteration of adenosine A<sub>1</sub> receptor binding in the post-ischaemic rat brain. *NeuroReport* 1994; 5: 1453–6.
203. Coelho JE, deMendonça A, Cunha RA, Ribeiro JA. Hypoxia induces a functional desensitisation of adenosine receptors. 4th Forum of European Neurosciences 2004; A048.6.
204. de Mendonça A, Costenla AR, Ribeiro JA. Persistence of the neuromodulatory effects of adenosine on synaptic transmission after long-term potentiation and long-term depression. *Brain Res* 2002; 932: 56–60.
205. Youssef FF, Addae JI, Stone TW. LTP-induced depression of response to hypoxia in hippocampus: Effects of adenosine receptor activation. *NeuroReport* 2003; 14: 1809–14.
206. Deckert J, Abel F, Kunig G et al. Loss of human hippocampal adenosine A<sub>1</sub> receptors in dementia: Evidence for lack of specificity. *Neurosci Lett* 1998; 244: 1–4.
207. Angulo E, Casado V, Mallol J et al. A<sub>1</sub> adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. *Brain Pathol* 2003; 13: 440–51.
208. Pinna A, Corsi C, Carta AR et al. Modification of adenosine extracellular levels and adenosine A<sub>2A</sub> receptor mRNA by dopamine denervation. *Eur J Pharmacol* 2002; 446: 75–82.

209. Tomiyama M, Kimura T, Maeda T et al. Upregulation of striatal adenosine A<sub>2A</sub> receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA. *Synapse* 2004; 52: 218–22.
210. Calon F, Dridi M, Hornykiewicz O et al. Increased adenosine A<sub>2A</sub> receptors in the brain of Parkinson's disease patients with dyskinesias. *Brain* 2004; 127: 1075–84.
211. Martinez-Mir MI, Probst A, Palacios JM. Adenosine A<sub>2</sub> receptors: Selective localization in the human basal ganglia and alterations with disease. *Neuroscience* 1991; 42: 697–706.
212. Hurley MJ, Mash DC, Jenner P. Adenosine A<sub>2A</sub> receptor mRNA expression in Parkinson's disease. *Neurosci Lett* 2000; 291: 54–8.
213. Varani K, Rigamonti D, Sipione S et al. Aberrant amplification of A<sub>2A</sub> receptor signaling in striatal cells expressing mutant huntingtin. *FASEB J* 2001; 15: 1245–7.
214. Glass M, Dragunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA<sub>A</sub> receptor alterations in the human basal ganglia in Huntington's disease. *Neuroscience* 2000; 97: 505–19.
215. Ishiwata K, Ogi N, Hayakawa N et al. Adenosine A<sub>2A</sub> receptor imaging with [<sup>11</sup>C]KF18446 PET in the rat brain after quinolinic acid lesion: Comparison with the dopamine receptor imaging. *Ann Nucl Med* 2002; 16: 467–75.
216. Canas P, Rebola N, Rodrigues RJ et al. Increased adenosine A<sub>2A</sub> immunoreactivity in activated rat microglia in culture. 4th Forum of European Neuroscience 2004; A223.9.
217. Trincavelli ML, Costa B, Tuscano D et al. Up-regulation of A<sub>2A</sub> adenosine receptors by proinflammatory cytokines in rat PC12 cells. *Biochem Pharmacol* 2002; 64: 625–31.
218. Arslan G, Kull B, Fredholm BB. Anoxia redistributes adenosine A<sub>2A</sub> receptors in PC12 cells and increases receptor-mediated formation of cAMP. *Naunyn-Schmiedeberg's Arch Pharmacol* 2002; 365: 150–7.
219. Suzuki T, Hashimoto S, Toyoda N et al. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. *Blood* 2000; 96: 2584–91.
220. Schnurr M, Toy T, Shin A et al. Role of adenosine receptors in regulating chemotaxis and cytokine production of plasmacytoid dendritic cells. *Blood* 2004; 103: 1391–7.
221. Panther E, Idzko M, Herouy Y et al. Expression and function of adenosine receptors in human dendritic cells. *FASEB J* 2001; 15: 1963–70.
222. Nguyen DK, Montesinos MC, Williams AJ et al. Th1 cytokines regulate adenosine receptors and their downstream signaling elements in human microvascular endothelial cells. *J Immunol* 2003; 171: 3991–8.
223. Leibovich SJ, Chen JF, Pinhal-Enfield G et al. Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A<sub>2A</sub> receptor agonists and endotoxin. *Am J Pathol* 2002; 160: 2231–44.
224. Deckert J, Brenner M, Durany N et al. Up-regulation of striatal adenosine A<sub>2A</sub> receptors in schizophrenia. *NeuroReport* 2003; 14: 313–6.
225. Gao Y, Phillis JW. CGS 15943, an adenosine A<sub>2</sub> receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. *Life Sci* 1994; 55: 61–5.
226. Phillis JW. The effects of selective A<sub>1</sub> and A<sub>2a</sub> adenosine receptor antagonists on cerebral ischemic injury in the gerbil. *Brain Res* 1995; 705: 79–84.
227. Von Lubitz DK, Lin RC, Jacobson KA. Cerebral ischemia in gerbils: Effects of acute and chronic treatment with adenosine A<sub>2A</sub> receptor agonist and antagonist. *Eur J Pharmacol* 1995; 287: 295–302.
228. Monopoli A, Lozza G, Forlani A et al. Blockade of adenosine A<sub>2A</sub> receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. *NeuroReport* 1998; 9: 3955–9.
229. Chen JF, Huang Z, Ma J et al. A<sub>2A</sub> adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. *J Neurosci* 1999; 19: 9192–200.
230. Tebano MT, Domenici MR, Popoli P. SCH 58261 differentially influences quinolinic acid-induced effects in striatal and in hippocampal slices. *Eur J Pharmacol* 2002; 450: 253–7.
231. Melani A, Pantoni L, Bordoni F et al. The selective A<sub>2A</sub> receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat. *Brain Res* 2003; 959: 243–50.
232. Behan WM, Stone TW. Enhanced neuronal damage by co-administration of quinolinic acid and free radicals, and protection by adenosine A<sub>2A</sub> receptor antagonists. *Br J Pharmacol* 2002; 135: 1435–42.
233. Petroni A, Papini N, Blasevich M, Galli C. Blockade of A<sub>2A</sub> adenosine receptors leads to *c-fos* inhibition in a rat model of brain ischemia. *Pharmacol Res* 2002; 45: 125–8.
234. Higashi H, Meno JR, Marwaha AS, Winn HR. Hippocampal injury and neurobehavioral deficits following hyperglycemic cerebral ischemia: Effect of theophylline and ZM 241385. *J Neurosurg* 2002; 96: 117–26.
235. Jones PA, Smith RA, Stone TW. Protection against hippocampal kainate excitotoxicity by intracerebral administration of an adenosine A<sub>2A</sub> receptor antagonist. *Brain Res* 1998; 800: 328–35.
236. Lee HK, Choi SS, Han KJ et al. Roles of adenosine receptors in the regulation of kainic acid-induced neurotoxic responses in mice. *Mol Brain Res* 2004; 125: 76–85.
237. Reggio R, Pezzola A, Popoli P. The intrastriatal injection of an adenosine A<sub>2</sub> receptor antagonist prevents frontal cortex EEG abnormalities in a rat model of Huntington's disease. *Brain Res* 1999; 831: 315–8.
238. Popoli P, Pintor A, Domenici MR et al. Blockade of striatal adenosine A<sub>2A</sub> receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: Possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum. *J Neurosci* 2002; 22: 1967–75.
239. Blum D, Galas MC, Pintor A et al. A dual role of adenosine A<sub>2A</sub> receptors in 3-nitropropionic acid-induced striatal lesions: Implications for the neuroprotective potential of A<sub>2A</sub> antagonists. *J Neurosci* 2003; 23: 5361–9.
240. Fink JS, Kalda A, Ryu H et al. Genetic and pharmacological inactivation of the adenosine A<sub>2A</sub> receptor attenuates 3-nitropropionic acid-induced striatal damage. *J Neurochem* 2004; 88: 538–44.
241. Alfinito PD, Wang SP, Manzano L et al. Adenosinergic protection of dopaminergic and GABAergic neurons against mitochondrial inhibition through receptors located in the substantia nigra and striatum, respectively. *J Neurosci* 2003; 23: 10982–7.
242. Chen JF, Xu K, Petzer JP et al. Neuroprotection by caffeine and A<sub>2A</sub> adenosine receptor inactivation in a model of Parkinson's disease. *J Neurosci* 2001; 21: RC143.
243. Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A<sub>2A</sub> receptor blockade in experimental models of Parkinson's disease. *J Neurochem* 2002; 80: 262–70.
244. Xu K, Xu YH, Chen JF, Schwarzschild MA. Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice. *Neurosci Lett* 2002; 322: 13–6.
245. Popoli P, Reggio R, Pezzola A. Effects of SCH 58261, an adenosine A<sub>2A</sub> receptor antagonist, on quinpirole-induced turning in 6-hydroxydopamine-lesioned rats. Lack of tolerance after chronic caffeine intake. *Neuropsychopharmacology* 2000; 22: 522–9.
246. Quarta D, Ferre S, Solinas M et al. Opposite modulatory roles for adenosine A<sub>1</sub> and A<sub>2A</sub> receptors on glutamate and dopamine release in the shell of the nucleus accumbens. Effects of chronic caffeine exposure. *J Neurochem* 2004; 88: 1151–8.
247. Monopoli A, Casati C, Lozza G et al. Cardiovascular pharmacology of the A<sub>2A</sub> adenosine receptor antagonist, SCH 58261, in the rat. *J Pharmacol Exp Ther* 1998; 285: 9–15.
248. Weiss SM, Whawell E, Upton R, Dourish CT. Potential for antipsychotic and psychotomimetic effects of A<sub>2A</sub> receptor modulation. *Neurology* 2003; 61(Suppl 6): S88–93.

249. O'Regan MH, Simpson RE, Perkins LM, Phillis JW. The selective A<sub>2</sub> adenosine receptor agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. *Neurosci Lett* 1992; 138: 169–72.
250. Marchi M, Raiteri L, Risso F et al. Effects of adenosine A<sub>1</sub> and A<sub>2A</sub> receptor activation on the evoked release of glutamate from rat cerebrocortical synaptosomes. *Br J Pharmacol* 2002; 136: 434–40.
251. Marcoli M, Raiteri L, Bonfanti A et al. Sensitivity to selective adenosine A<sub>1</sub> and A<sub>2A</sub> receptor antagonists of the release of glutamate induced by ischemia in rat cerebrocortical slices. *Neuropharmacology* 2003; 45: 201–10.
252. Nikbakht MR, Stone TW. Suppression of presynaptic responses to adenosine by activation of NMDA receptors. *Eur J Pharmacol* 2001; 427: 13–25.
253. Corsi C, Melani A, Bianchi L et al. Striatal A<sub>2A</sub> adenosine receptors differentially regulate spontaneous and K<sup>+</sup>-evoked glutamate release *in vivo* in young and aged rats. *NeuroReport* 1999; 10: 687–91.
254. Corsi C, Melani A, Bianchi L, Pedata F. Striatal A<sub>2A</sub> adenosine receptor antagonism differentially modifies striatal glutamate outflow *in vivo* in young and aged rats. *NeuroReport*. 2000; 11: 2591–5.
255. Pintor A, Quarta D, Pezzola A et al. SCH 58261 (an adenosine A<sub>2A</sub> receptor antagonist) reduces, only at low doses, K<sup>+</sup>-evoked glutamate release in the striatum. *Eur J Pharmacol* 2001; 421: 177–80.
256. Gianfriddo M, Corsi C, Melani A et al. Adenosine A<sub>2A</sub> antagonism increases striatal glutamate outflow in the quinolinic acid rat model of Huntington's disease. *Brain Res* 2003; 979: 225–9.
257. Tebano MT, Pintor A, Frank C et al. Adenosine A<sub>2A</sub> receptor blockade differentially influences excitotoxic mechanisms at pre- and postsynaptic sites in the rat striatum. *J Neurosci Res* 2004; 77: 100–7.
258. Popoli P, Frank C, Tebano MT et al. Modulation of glutamate release and excitotoxicity by adenosine A<sub>2A</sub> receptors. *Neurology* 2003; 61(Suppl 6): S69–71.
259. Sebastião AM, de Mendonça A, Moreira T, Ribeiro JA. Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. *J Neurosci* 2001; 21: 8564–71.
260. Latini S, Bordoni F, Corradetti R et al. Effect of A<sub>2A</sub> adenosine receptor stimulation and antagonism on synaptic depression induced by *in vitro* ischaemia in rat hippocampal slices. *Br J Pharmacol* 1999; 128: 1035–44.
261. Pintor A, Galluzzo M, Grieco R et al. Adenosine A<sub>2A</sub> receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. *J Neurochem* 2004; 89: 152–6.
262. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischaemia is mainly by reversed uptake. *Nature* 2000; 403: 316–21.
263. Dall'Igna OP, Porciúncula LO, Souza DO et al. Neuroprotection by caffeine and adenosine A<sub>2A</sub> receptor blockade of beta-amyloid neurotoxicity. *Br J Pharmacol* 2003; 138: 1207–9.
264. Porciúncula LO, Oliveira CR, Cunha RA. Blockade of A<sub>2A</sub> adenosine receptors prevents synaptic apoptosis provoked by beta amyloid peptide in rat cultured hippocampal neurons. 4th Forum of European Neuroscience 2004; A195.4.
265. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. *Science* 2002; 297: 353–6.
266. Turner PR, O'Connor K, Tate WP, Abraham WC. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. *Prog Neurobiol* 2003; 70: 1–32.
267. Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A<sub>2A</sub> receptors: Implications for the treatment of Parkinson's disease. *J Neurosci* 2000; 20: 7782–9.
268. Wirkner K, Gerevich Z, Krause T et al. Adenosine A<sub>2A</sub> receptor-induced inhibition of NMDA and GABA<sub>A</sub> receptor-mediated synaptic currents in a subpopulation of rat striatal neurons. *Neuropharmacology* 2004; 46: 994–1007.
269. Gerevich Z, Wirkner K, Illes P. Adenosine A<sub>2A</sub> receptors inhibit the N-methyl-D-aspartate component of excitatory synaptic currents in rat striatal neurons. *Eur J Pharmacol* 2002; 451: 161–4.
270. Robledo P, Ursu G, Mahy N. Effects of adenosine and gamma-aminobutyric acid A receptor antagonists on N-methyl-D-aspartate induced neurotoxicity in the rat hippocampus. *Hippocampus* 1999; 9: 527–33.
271. Huang NK, Lin YW, Huang CL et al. Activation of protein kinase A and atypical protein kinase C by A<sub>2A</sub> adenosine receptors antagonizes apoptosis due to serum deprivation in PC12 cells. *J Biol Chem* 2001; 276: 13838–46.
272. Huang NK. Adenosine A<sub>2A</sub> receptors regulate oxidative stress formation in rat pheochromocytoma PC12 cells during serum deprivation. *Neurosci Lett* 2003; 350: 127–31.
273. Ramirez SH, Fan S, Maguire CA et al. Activation of adenosine A<sub>2A</sub> receptor protects sympathetic neurons against nerve growth factor withdrawal. *J Neurosci Res* 2004; 77: 258–69.
274. Walker BA, Rocchini C, Boone RH et al. Adenosine A<sub>2A</sub> receptor activation delays apoptosis in human neutrophils. *J Immunol* 1997; 158: 2926–31.
275. Yasui K, Agematsu K, Shinozaki K et al. Theophylline induces neutrophil apoptosis through adenosine A<sub>2A</sub> receptor antagonism. *J Leukoc Biol* 2000; 67: 529–35.
276. Zhao ZQ, Budde JM, Morris C et al. Adenosine attenuates reperfusion-induced apoptotic cell death by modulating expression of Bcl-2 and Bax proteins. *J Mol Cell Cardiol* 2001; 33: 57–68.
277. Schubert P, Rudolphi K. Interfering with the pathologic activation of microglial cells and astrocytes in dementia. *Alzheimer Dis Assoc Disord* 1998; 12(Suppl 2): S21–8.
278. Allan SM, Rothwell NJ. Inflammation in central nervous system injury. *Philos Trans R Soc Lond, B* 2003; 358: 1669–77.
279. Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: Mechanisms and strategies for therapeutic intervention. *J Pharmacol Exp Ther* 2003; 304: 1–7.
280. Neuman H. The immunological microenvironment in the CNS: Implications on neuronal cell death and survival. *J Neural Transm* 2000; 59: 59–68.
281. Kato H, Walz W. The initiation of the microglia response. *Brain Pathol* 2000; 10: 137–43.
282. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. *Neurobiol Aging* 2000; 21: 383–421.
283. Kreutzberg GW. Microglia: A sensor for pathological events in the CNS. *Trends Neurosci* 1996; 19: 312–8.
284. Porciúncula LO, Canas P, Oliveira CR, Cunha RA. Blockade of adenosine A<sub>2A</sub> receptors prevents kainate-induced convulsions and neuronal cell death. 4th International Symposium of Nucleosides and Nucleotides 2004; 69T.
285. Rebola N, Barry C, Oliveira CR et al. Blockade of adenosine A<sub>2A</sub> receptors attenuates inflammatory responses in the central nervous systems. 4th Forum of European Neuroscience 2004; A023.11.
286. Kim WG, Mohny RP, Wilson B et al. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity: Role of microglia. *J Neurosci* 2000; 20: 6309–16.
287. Kloss CU, Bohatscheck M, Kreutzberg GW, Raivich G. Effect of lipopolysaccharide on the morphology and integrin immunoreactivity of ramified microglia in mouse brain and in cell culture. *Exp Neurol* 2001; 168: 32–46.
288. Hanisch UK. Microglia as a source and target of cytokines. *Glia* 2002; 40: 140–55.
289. de Simone R, Ajmone-Cat MA, Minghetti L. Atypical anti-inflammatory activation of microglia induced by apoptotic neurons: Possible role of phosphatidylserine–phosphatidylserine receptor interaction. *Mol Neurobiol* 2004; 29: 197–212.
290. Jensen MB, Finsen B, Zimmer J. Morphological and immunophenotypic microglial changes in denervated fascia dentate of adult rats: Correlation with blood brain barrier damage and astroglial reactions. *Exp Neurol* 1997; 143: 103–6.
291. Lyons SA, Pastor A, Ohlemeyer C et al. Distinct physiologic properties of microglia and blood-borne cells in rat brain slices after

- permanent middle cerebral artery occlusion. *J Cereb Blood Flow Metab* 2000; 20: 1537–49.
292. Yu L, Huang H, Mariana J. et al. Selective inactivation or reconstitution of adenosine A<sub>2A</sub> receptors in bone marrow cells reveals their critical role in the development of ischemic brain injury. 4th International Symposium of Nucleosides and Nucleotides 2004; 67T.
  293. Ballabh P, Braun A, Nedergaard M. The blood–brain barrier: An overview: Structure, regulation, and clinical implications. *Neurobiol Dis* 2004; 16: 1–13.
  294. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. *Nature* 2001; 414: 916–20.
  295. Sitkovsky MV, Lukashev D, Apasov S et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A<sub>2A</sub> receptors. *Annu Rev Immunol* 2004; 22: 657–82.
  296. Hasko G, Cronstein BN. Adenosine: An endogenous regulator of innate immunity. *Trends Immunol* 2004; 25: 33–9.
  297. Cargnoni A, Ceconi C, Boraso A et al. Role of A<sub>2A</sub> receptor in the modulation of myocardial reperfusion damage. *J Cardiovasc Pharmacol* 1999; 33: 883–93.
  298. Maddock HL, Broadley KJ, Bril A, Khandoudi N. Role of endothelium in ischaemia-induced myocardial dysfunction of isolated working hearts: Cardioprotection by activation of adenosine A<sub>2A</sub> receptors. *J Auton Pharmacol* 2001; 21: 263–71.
  299. Platts SH, Linden J, Duling BR. Rapid modification of the glycocalyx caused by ischemia–reperfusion is inhibited by adenosine A<sub>2A</sub> receptor activation. *Am J Physiol* 2003; 284: H2360–7.
  300. McPherson JA, Barringham KG, Bishop GG et al. Adenosine A<sub>2A</sub> receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. *Arterioscler Thromb Vasc Biol* 2001; 21: 791–6.
  301. Okusa MD, Linden J, Huang L et al. A<sub>2A</sub> adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. *Am J Physiol* 2000; 279: F809–18.
  302. Day YJ, Huang L, McDuffie MJ et al. Renal protection from ischemia mediated by A<sub>2A</sub> adenosine receptors on bone marrow-derived cells. *J Clin Invest* 2003; 112: 883–91.
  303. Harada N, Okajima K, Murakami K et al. Adenosine and selective A<sub>2A</sub> receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. *J Pharmacol Exp Ther* 2000; 294: 1034–42.
  304. Day YJ, Marshall MA, Huang L et al. Protection from ischemic liver injury by activation of A<sub>2A</sub> adenosine receptors during reperfusion: Inhibition of chemokine induction. *Am J Physiol* 2004; 286: G285–93.
  305. Khimenko PL, Moore TM, Hill LW et al. Adenosine A<sub>2</sub> receptors reverse ischemia–reperfusion lung injury independent of beta-receptors. *J Appl Physiol* 1995; 78: 990–6.
  306. Ross SD, Tribble CG, Linden J et al. Selective adenosine-A<sub>2A</sub> activation reduces lung reperfusion injury following transplantation. *J Heart Lung Transplant* 1999; 18: 994–1002.
  307. Cohen SB, Gill SS, Baer GS et al. Reducing joint destruction due to septic arthritis using an adenosine A<sub>2A</sub> receptor agonist. *J Orthop Res* 2004; 22: 427–35.
  308. Peirce SM, Skalak TC, Rieger JM et al. Selective A<sub>2A</sub> adenosine receptor activation reduces skin pressure ulcer formation and inflammation. *Am J Physiol* 2001; 281: H67–74.
  309. Montesinos MC, Desai A, Chen JF et al. Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A<sub>2A</sub> receptors. *Am J Pathol* 2002; 160: 2009–18.
  310. Cassada DC, Tribble CG, Laubach VE et al. An adenosine A<sub>2A</sub> agonist, ATL-146e, reduces paralysis and apoptosis during rabbit spinal cord reperfusion. *J Vasc Surg* 2001; 34: 482–8.
  311. Cassada DC, Tribble CG, Long SM et al. Adenosine A<sub>2A</sub> analogue ATL-146e reduces systemic tumor necrosis factor- $\alpha$  and spinal cord capillary platelet–endothelial cell adhesion molecule-1 expression after spinal cord ischemia. *J Vasc Surg* 2002; 35: 994–8.
  312. Mayne M, Fotheringham J, Yan HJ et al. Adenosine A<sub>2A</sub> receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. *Ann Neurol* 2001; 49: 727–35.
  313. Sullivan GW, Linden J, Buster BL, Scheld WM. Neutrophil A<sub>2A</sub> adenosine receptor inhibits inflammation in a rat model of meningitis: Synergy with the type IV phosphodiesterase inhibitor, rolipram. *J Infect Dis* 1999; 180: 1550–60.
  314. Ritchie PK, Spangelo BL, Krzymowski DK et al. Adenosine increases interleukin 6 release and decreases tumour necrosis factor release from rat adrenal zona glomerulosa cells, ovarian cells, anterior pituitary cells, and peritoneal macrophages. *Cytokine* 1997; 9: 187–98.
  315. Hasko G, Kuhel DG, Chen JF et al. Adenosine inhibits IL-12 and TNF- $\alpha$  production via adenosine A<sub>2A</sub> receptor-dependent and independent mechanisms. *FASEB J* 2000; 14: 2065–74.
  316. Pinhal-Enfield G, Ramanathan M, Hasko G et al. An angiogenic switch in macrophages involving synergy between Toll-like receptors 2, 4, 7, and 9 and adenosine A<sub>2A</sub> receptors. *Am J Pathol* 2003; 163: 711–21.
  317. Bouma MG, Jeunhomme TM, Boyle DL et al. Adenosine inhibits neutrophil degranulation in activated human whole blood: Involvement of adenosine A<sub>2</sub> and A<sub>3</sub> receptors. *J Immunol* 1997; 158: 5400–8.
  318. Link AA, Kino T, Worth JA et al. Ligand-activation of the adenosine A<sub>2A</sub> receptors inhibits IL-12 production by human monocytes. *J Immunol* 2000; 164: 436–42.
  319. Bshesh K, Zhao B, Spight D et al. The A<sub>2A</sub> receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. *J Leukoc Biol* 2002; 72: 1027–36.
  320. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A<sub>2A</sub> extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. *Blood* 1997; 90: 1600–10.
  321. Apasov S, Chen JF, Smith P, Sitkovsky M. A<sub>2A</sub> receptor dependent and A<sub>2A</sub> receptor independent effects of extracellular adenosine on murine thymocytes in conditions of adenosine deaminase deficiency. *Blood* 2000; 95: 3859–67.
  322. Linden J. CD4<sup>+</sup> T cells are targets of adenosine-mediated tissue protection from ischemia–reperfusion in jury. 4th International Symposium of Nucleosides and Nucleotides 2004.
  323. Kipnis J, Mizrahi T, Hauben E et al. Neuroprotective autoimmunity: Naturally occurring CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells suppress the ability to withstand injury to the central nervous system. *Proc Natl Acad Sci U S A* 2002; 99: 15620–5.
  324. Kipnis J, Cardon M, Avidan H et al. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4<sup>+</sup>CD25<sup>+</sup> regulatory T-cell activity: Implications for neurodegeneration. *J Neurosci* 2004; 24: 6133–43.
  325. Stone TW. Purines and neuroprotection. *Adv Exp Med Biol* 2002; 513: 249–80.
  326. Richardson PJ, Kase H, Jenner PG. Adenosine A<sub>2A</sub> receptor antagonists as new agents for the treatment of Parkinson's disease. *Trends Pharmacol Sci* 1997; 18: 338–44.
  327. Schwarzschild MA, Xu K, Oztas E et al. Neuroprotection by caffeine and more specific A<sub>2A</sub> receptor antagonists in animal models of Parkinson's disease. *Neurology* 2003; 61(Suppl 6): S55–61.
  328. Chen JF, Fredduzzi S, Bastia E et al. Adenosine A<sub>2A</sub> receptors in neuroadaptation to repeated dopaminergic stimulation: Implications for the treatment of dyskinesias in Parkinson's disease. *Neurology* 2003; 61(Suppl 6): S74–81.
  329. Kase H, Aoyama S, Ichimura M et al. Progress in pursuit of therapeutic A<sub>2A</sub> antagonists: The adenosine A<sub>2A</sub> receptor selective antagonist KW6002: Research and development toward a novel nondopaminergic therapy for Parkinson's disease. *Neurology* 2003; 61(Suppl 6): S97–100.
  330. Huber A, Padrun V, Deglon N et al. Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. *Proc Natl Acad Sci USA* 2001; 98: 7611–6.

331. Gouder N, Fritschy JM, Boison D. Seizure suppression by adenosine A<sub>1</sub> receptor activation in a mouse model of pharmacoresistant epilepsy. *Epilepsia* 2003; 44: 877–85.
332. Tsutsui S, Schnermann J, Noorbakhsh F et al. A<sub>1</sub> adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. *J Neurosci* 2004; 24: 1521–9.
333. Richter A, Hamann M. Effects of adenosine receptor agonists and antagonists in a genetic animal model of primary paroxysmal dystonia. *Br J Pharmacol* 2001; 134: 343–52.
334. Blum D, Gall D, Galas MC et al. The adenosine A<sub>1</sub> receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. *J Neurosci* 2002; 22: 9122–33.
335. Lu Y, Chung HJ, Li Y, Rosenberg PA. NMDA receptor-mediated extracellular adenosine accumulation in rat forebrain neurons in culture is associated with inhibition of adenosine kinase. *Eur J Neurosci* 2003; 17: 1213–22.
336. Rivkees SA. The ontogeny of cardiac and neural A<sub>1</sub> adenosine receptor expression in rats. *Dev Brain Res* 1995; 89: 202–13.
337. Doriat JF, Humbert AC, Daval JL. Brain maturation of high-affinity adenosine A<sub>2</sub> receptors and their coupling to G-proteins. *Dev Brain Res* 1996; 93: 1–9.
338. Doriat JF, Koziel V, Humbert AC, Daval JL. Medium- and long-term alterations of brain A<sub>1</sub> and A<sub>2A</sub> adenosine receptor characteristics following repeated seizures in developing rats. *Epilepsy Res* 1999; 35: 219–28.
339. Johansson B, Georgiev V, Fredholm BB. Distribution and postnatal ontogeny of adenosine A<sub>2A</sub> receptors in rat brain: Comparison with dopamine receptors. *Neuroscience* 1997; 80: 1187–207.
340. Aden U, Lindstrom K, Bona E et al. Changes in adenosine receptors in the neonatal rat brain following hypoxic ischemia. *Pediatr Res* 2000; 48: 177–83.
341. Aden U, Leverin AL, Hagberg H, Fredholm BB. Adenosine A<sub>1</sub> receptor agonism in the immature rat brain and heart. *Eur J Pharmacol* 2001; 426: 185–92.
342. Guillet R, Dunham L. Neonatal caffeine exposure and seizure susceptibility in adult rats. *Epilepsia* 1995; 36: 743–9.
343. Dzhala V, Desfreres L, Melyan Z et al. Epileptogenic action of caffeine during anoxia in the neonatal rat hippocampus. *Ann Neurol* 1999; 46: 95–102.
344. Hunter CJ, Bennet L, Power GG et al. Key neuroprotective role for endogenous adenosine A<sub>1</sub> receptor activation during asphyxia in the fetal sheep. *Stroke* 2003; 34: 2240–5.
345. Turner CP, Seli M, Ment L et al. A<sub>1</sub> adenosine receptors mediate hypoxia-induced ventriculomegaly. *Proc Natl Acad Sci USA* 2003; 100: 11718–22.
346. Turner CP, Yan H, Schwartz M et al. A<sub>1</sub> adenosine receptor activation induces ventriculomegaly and white matter loss. *NeuroReport* 2002; 13: 1199–204.
347. Blood AB, Hunter CJ, Power GG. Adenosine mediates decreased cerebral metabolic rate and increased cerebral blood flow during acute moderate hypoxia in the near-term fetal sheep. *J Physiol* 2003; 553: 935–45.
348. Psarropoulou C, Kostopoulos G, Haas HL. An electrophysiological study of the ontogenesis of adenosine receptors in the CA<sub>1</sub> area of rat hippocampus. *Dev Brain Res* 1990; 55: 147–50.
349. Rivkees SA, Zhao Z, Porter G, Turner C. Influences of adenosine on the fetus and newborn. *Mol Genet Metab* 2001; 74: 160–71.
350. Bona E, Aden U, Gilland E et al. Neonatal cerebral hypoxia-ischemia: The effect of adenosine receptor antagonists. *Neuropharmacology* 1997; 36: 1327–38.
351. Shaban M, Smith RA, Stone TW. Adenosine receptor-mediated inhibition of neurite outgrowth from cultured sensory neurons is via an A<sub>1</sub> receptor and is reduced by nerve growth factor. *Dev Brain Res* 1998; 105: 167–73.
352. Thevananther S, Rivera A, Rivkees SA. A<sub>1</sub> adenosine receptor activation inhibits neurite process formation by Rho kinase-mediated pathways. *NeuroReport* 2001; 12: 3057–63.
353. Gidday JM, Fitzgibbons JC, Shah AR et al. Reduction in cerebral ischemic injury in the newborn rat by potentiation of endogenous adenosine. *Pediatr Res* 1995; 38: 306–11.
354. Aden U, Halldner L, Lagercrantz H et al. Aggravated brain damage after hypoxic ischemia in immature adenosine A<sub>2A</sub> knockout mice. *Stroke* 2003; 34: 739–44.
355. Mody I, MacDonald JF. NMDA receptor-dependent excitotoxicity: The role of intracellular Ca<sup>2+</sup> release. *Trends Pharmacol Sci* 1995; 16: 356–9.
356. Turner CP, Pulciani D, Rivkees SA. Reduction in intracellular calcium levels induces injury in developing neurons. *Exp Neurol* 2002; 178: 21–32.
357. Scholz KP, Miller RJ. Analysis of adenosine actions on Ca<sup>2+</sup> currents and synaptic transmission in cultured rat hippocampal pyramidal neurones. *J Physiol* 1991; 435: 373–93.
358. Obrietan K, Belousov AB, Heller HC, van den Pol AN. Adenosine pre- and postsynaptic modulation of glutamate-dependent calcium activity in hypothalamic neurons. *J Neurophysiol* 1995; 74: 2150–62.
359. Sturm CD, Frisella WA, Yoon KW. Attenuation of potassium cyanide-mediated neuronal cell death by adenosine. *J Neurosurg* 1993; 79: 111–5.
360. Daval JL, Nicolas F. Opposite effects of cyclohexyladenosine and theophylline on hypoxic damage in cultured neurons. *Neurosci Lett* 1994; 175: 114–6.
361. Logan M, Sweeney MI. Adenosine A<sub>1</sub> receptor activation preferentially protects cultured cerebellar neurons *versus* astrocytes against hypoxia-induced death. *Mol Chem Neuropathol* 1997; 31: 119–33.
362. Lobner D, Choi DW. Dipyridamole increases oxygen-glucose deprivation-induced injury in cortical cell culture. *Stroke* 1994; 25: 2085–9.
363. Barth A, Newell DW, Nguyen LB et al. Neurotoxicity in organotypic hippocampal slices mediated by adenosine analogues and nitric oxide. *Brain Res* 1997; 762: 79–88.
364. Brooke SM, Sapolsky RM. A cautionary note: The actions of adenosine agonists and antagonists may be reversed under certain conditions in primary cultures. *Brain Res Bull* 2000; 51: 307–12.
365. Ferreira JM, Paes-de-Carvalho R. Long-term activation of adenosine A<sub>2a</sub> receptors blocks glutamate excitotoxicity in cultures of avian retinal neurons. *Brain Res* 2001; 900: 169–76.
366. Paes-de-Carvalho R, Maia GA, Ferreira JM. Adenosine regulates the survival of avian retinal neurons and photoreceptors in culture. *Neurochem Res* 2003; 28: 1583–90.
367. Lynch JJ, Alexander KM, Jarvis MF, Kowaluk EA. Inhibition of adenosine kinase during oxygen-glucose deprivation in rat cortical neuronal cultures. *Neurosci Lett* 1998; 252: 207–10.
368. Lobner D. Saturation of neuroprotective effects of adenosine in cortical culture. *NeuroReport* 2002; 13: 2075–8.
369. Cheng JT, Liu IM, Juang SW, Jou SB. Decrease of adenosine A<sub>1</sub> receptor gene expression in cerebral cortex of aged rats. *Neurosci Lett* 2000; 283: 227–9.
370. Pagonopoulou O, Angelatou F. Reduction of A<sub>1</sub> adenosine receptors in cortex, hippocampus and cerebellum in ageing mouse brain. *NeuroReport* 1992; 3: 735–7.
371. Araki T, Kato H, Kanai Y, Kogure K. Selective changes of neurotransmitter receptors in middle-aged gerbil brain. *Neurochem Int* 1993; 23: 541–8.
372. Cunha RA, Constantino MC, Sebastião AM, Ribeiro JA. Modification of A<sub>1</sub> and A<sub>2a</sub> adenosine receptor binding in aged striatum, hippocampus and cortex of the rat. *NeuroReport* 1995; 6: 1583–8.
373. Cunha RA, Constantino MD, Fonseca E, Ribeiro JA. Age-dependent decrease in adenosine A<sub>1</sub> receptor binding sites in the rat brain. Effect of *cis* unsaturated free fatty acids. *Eur J Biochem* 2001; 268: 2939–47.
374. Ekonomou A, Pagonopoulou O, Angelatou F. Age-dependent changes in adenosine A<sub>1</sub> receptor and uptake site binding in the mouse brain: An autoradiographic study. *J Neurosci Res* 2000; 60: 257–65.
375. Sperlagh B, Zsilla G, Baranyi M et al. Age-dependent changes of presynaptic neuromodulation via A<sub>1</sub>-adenosine receptors in rat hippocampal slices. *Int J Dev Neurosci* 1997; 15: 739–47.

376. Fredholm BB, Johansson B, Lindstrom K, Wahlstrom G. Age-dependent changes in adenosine receptors are not modified by life-long intermittent alcohol administration. *Brain Res* 1998; 791: 177–85.
377. Lopes LV, Cunha RA, Ribeiro JA. Increase in the number, G protein coupling, and efficiency of facilitatory adenosine  $A_{2A}$  receptors in the limbic cortex, but not striatum, of aged rats. *J Neurochem* 1999; 73: 1733–8.
378. Giovannelli L, Giovannini MG, Pedata F, Pepeu G. Purinergic modulation of cortical acetylcholine release is decreased in aging rats. *Exp Gerontol* 1988; 23: 175–81.
379. Pedata F, Slavikova J, Kotas A, Pepeu G. Acetylcholine release from rat cortical slices during postnatal development and aging. *Neurobiol Aging* 1983; 4: 31–5.
380. Sebastião AM, Cunha RA, de Mendonca A, Ribeiro JA. Modification of adenosine modulation of synaptic transmission in the hippocampus of aged rats. *Br J Pharmacol* 2000; 131: 1629–34.
381. Schiffmann SN, Vanderhaeghen JJ. Age-related loss of mRNA encoding adenosine  $A_2$  receptor in the rat striatum. *Neurosci Lett* 1993; 158: 121–4.
382. Popoli P, Betto P, Rimondini R et al. Age-related alteration of the adenosine/dopamine balance in the rat striatum. *Brain Res* 1998; 795: 297–300.
383. Alfaro TM, Vigia E, Oliveira CR, Cunha RA. Effect of free radicals on adenosine  $A_{2A}$  and dopamine  $D_2$  receptors in the striatum of young adult and aged rats. *Neurochem Int* 2004; 45: 733–8.
384. Corsi C, Melani A, Bianchi L, Pedata F. Striatal  $A_{2A}$  adenosine receptor antagonism differentially modifies striatal glutamate outflow *in vivo* in young and aged rats. *NeuroReport* 2000; 11: 2591–5.
385. Popoli P, Reggio R, Pezzola A, Fuxe K, Ferré S. Adenosine  $A_1$  and  $A_{2A}$  receptor antagonists stimulate motor activity: Evidence for an increased effectiveness in aged rats. *Neurosci Lett* 1998; 251: 201–4.
386. Barnes CA. Normal aging: Regionally specific changes in hippocampal synaptic transmission. *Trends Neurosci* 1994; 17: 13–8.
387. Rosenzweig ES, Barnes CA. Impact of aging on hippocampal function: Plasticity, network dynamics, and cognition. *Prog Neurobiol* 2003; 69: 143–79.
388. Gimenez-Llort L, Fernandez-Teruel A, Escorihuela RM et al. Mice lacking the adenosine  $A_1$  receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. *Eur J Neurosci* 2002; 16: 547–50.
389. Corsi C, Pazzagli M, Bianchi L et al. *In vivo* amino acid release from the striatum of aging rats: Adenosine modulation. *Neurobiol Aging* 1997; 18: 243–50.
390. Bauman LA, Mahle CD, Boissard CG, Gribkoff VK. Age-dependence of effects of  $A_1$  adenosine receptor antagonism in rat hippocampal slices. *J Neurophysiol* 1992; 68: 629–38.
391. Gribkoff VK, Bauman LA. Endogenous adenosine contributes to hypoxic synaptic depression in hippocampus from young and aged rats. *J Neurophysiol* 1992; 68: 620–8.
392. Costenla AR, de Mendonca A, Ribeiro JA. Adenosine modulates synaptic plasticity in hippocampal slices from aged rats. *Brain Res* 1999; 851: 228–34.
393. Cai G, Wang HY, Gao E et al. Reduced adenosine  $A_1$  receptor and  $G\alpha$  protein coupling in rat ventricular myocardium during aging. *Circ Res* 1997; 81: 1065–71.
394. Headrick JP, Willems L, Ashton KJ et al. Ischaemic tolerance in aged mouse myocardium: The role of adenosine and effects of  $A_1$  adenosine receptor overexpression. *J Physiol* 2003; 549: 823–33.
395. Pereira MF, Cunha RA, Ribeiro JA. Tonic adenosine neuromodulation is preserved in motor nerve endings of aged rats. *Neurochem Int* 2000; 36: 563–6.
396. Kalaria RN, Sromek S, Wilcox BJ, Unnerstall JR. Hippocampal adenosine  $A_1$  receptors are decreased in Alzheimer's disease. *Neurosci Lett* 1990; 118: 257–60.
397. Ulas J, Brunner LC, Nguyen L, Cotman CW. Reduced density of adenosine  $A_1$  receptors and preserved coupling of adenosine  $A_1$  receptors to G proteins in Alzheimer hippocampus: A quantitative autoradiographic study. *Neuroscience* 1993; 52: 843–54.